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Abstract
BACKGROUND: Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood
disorder that is behaviorally characterized by developmentally inappropriate levels of inat-
tention, impulsivity and hyperactivity. Among several hypotheses of ADHD etiology the
prevailing hypothesis implicates a hypodopaminergic system due largely to the successes
of the use of psychostimulants such as methylphenidate, that increase extracellular lev-
els of dopamine (DA) and/or norepinephrine (NE) for the treatment of symptoms. In
this study, the spontaneously hypertensive rat (SHR), the most widely accepted model
for ADHD, is compared with the Wistar-Kyoto (WKY) and Sprague-Dawley (SD) rat
strains as controls. METHODS: The SHR and WKY rat strains were first genetically
screened for purity using SNPs from three chromosomal sites. In vivo chronoamperome-
try, a technique that allows for the measurement of micromolar DA concentrations at high
spatial (30 µm) and temporal (5 Hz) resolutions was set up for the first time in Africa
by this laboratory. This technique was used to measure a) the level of dopamine release
by potassium stimulation and b) the rate of clearance of exogenously applied dopamine.
Recordings were taken from within the anaesthetized rat’s striatum (AP 1 mm; ML 2.5
mm from bregma (Paxinos and Watson, 2005)) every 500 µm from DV co-ordinates 3.5 to
DV 7.5 mm relative to dura, between P 32 and P 37. Behaviour in the open field appara-
tus and voluntary running were measured in response to methylphenidate or guanfacine
treatment, since an alternative noradrenergic hypothesis suggests that a hypernoradren-
ergic system may be the cause of ADHD symptoms, and α2A-adrenoreceptor agonists
such as guanfacine have been shown to be effective in treating ADHD. RESULTS: Initial
genetic screening suggested a possible but unconfirmed crossing of SHR and SD strains.
The in vivo chronoamperometry study revealed that SHR release more dopamine than
SD and WKY strains, in response to potassium stimulation. SHR cleared exogenously
applied dopamine at rates that were more similar to SD and significantly faster than that
of WKY. Methylphenidate and guanfacine treatment had no effect on voluntary running
or open field behaviour in any strain. CONCLUSION: SHR were significantly more active
than WKY in terms of voluntary behaviour in cages with attached running wheels and
in the open field. The SHR showed decreased DAT activity in the rising phase of the DA
peaks while the WKY showed decreased DAT activity in both the rising and falling phase
of the DA peaks. Additional genetic screening is required to confirm whether an SHR
and SD crossing of strains occured, however the present results suggest that new animal
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Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood disorder that is behav-
iorally characterized by developmentally inappropriate levels of inattention, impulsivity
and/or hyperactivity (American Psychiatric Association, 2000). Three subtypes of ADHD
have been defined, including the predominantly inattentive (ADHD-I), the predominantly
hyperactive (ADHD-H) and a combined sub type (ADHD-C), each diagnosed by various
specific behaviours that are evident in at least two or more settings (American Psychiatric
Association, 2000).
Children with ADHD have been shown to be at increased risk of school failure, aca-
demic underachievement, juvenile delinquency, substance abuse, incarceration, eventually
receiving lower paying occupations in adulthood, divorce, and of living in poverty (Fis-
cher et al., 1993; Barkley et al., 2004, 2006; Loo et al., 2009). ADHD is also associated
with other psychiatric disorders in about two thirds of cases (Gillberg et al., 2004). In
a study of Swedish school-aged children, approximately 50% and 25% of children with
ADHD also met the criteria for Oppositional Defiance Disorder (ODD) and Conduct Dis-
order (CD), respectively (Cormier, 2008; Kadesjo and Gillberg, 2001). Other documented
co-morbidities include Bipolar Disorder (BD) (Bernardi et al., 2010), Antisocial Personal-
ity Disorder (ASPD) (Black et al., 2010), Developmental Co-ordination Disorder (DCD)
(Bart et al., 2010), Autism Spectrum Disorder (ASD), Obsessive Compulsive Disorder
(OCD), depression and anxiety disorder and tic disorders (Cormier, 2008; Spencer et al.,
1999a,b). The impulsive characteristic of ADHD leads to a certain disregard of con-
sequences and carelessness, together with the variety of co-morbidities, they frequently
result in harming themselves or others (Blum et al., 2008).
The symptoms of ADHD are usually discerned before the age of seven (Tan and
Appleton, 2005), and occurs in between 3% to 7% of school-aged children (Faraone et al.,
2003). Although symptoms of this disorder have been known to dissipate as the patient
age increases, 70% of children diagnosed with ADHD, or between 1% to 6% of the adult
population, continue to exhibit symptoms in adult life (Biederman, 1998; Kessler et al.,
2005; Cormier, 2008; Kolar, 2008). A recent German study on the psychological status
of soldiers with ADHD showed that cumulative adaptability problems were significantly
correlated with agression, partnership problems and dissocial symptoms (Zimmermann
et al., 2010). This study concluded that although ADHD does not automatically exclude
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soldiers from military duty, 44.4% with ADHD were not able to continue their service
(Zimmermann et al., 2010).
In the United States, it was estimated that two-and-a-half billion dollars per year
are spent on the diagnosis and treatment of ADHD (Chan et al., 2002). This disorder
is extremely costly to the afflicted individuals, their families, and society (Birnbaum
et al., 2005), and when children go undiagnosed and untreated, further potential costs are
immense (Blum et al., 2008). In South Africa. the contraction and spread of HIV/AIDS
is of particular concern, since ADHD is also associated with increased sexual risk taking
behaviour in adolescents (Brown et al., 2010).
1.2 Treatments
The first report of successful drug treatment for ‘hyperactivity’ occurred in 1937, with
the use of dl -amphetamine (Bradley, 1937; Heal et al., 2008; Cormier, 2008). Currently,
stimulant treatments include methylphenidate (Ritalin, Concerta), dextroamphetamine
(Dexedrine) and a dl -amphetamine extended release, mixed salts formulation (Adderal
XR); non-stimulant medications include atomoxetine, bupropion, tricyclic antidepres-
sants, clonidine, guanfacine and modafinil (Strange, 2008; Kolar, 2008). Some side ef-
fects of stimulant treatment include decreased appetite, headache, insomnia, nausea, dry-
mouth, irritability, anxiety, nervousness, increased blood pressure and weight loss; while
non-stimulant treatments have side effects such as dry mouth, drowsiness and constipa-
tion (Kolar, 2008; Medori et al., 2008). In rare cases stimulants have caused seizures,
psychosis, hypertension, severe anorexia and hepatotoxicity (Kolar, 2008; Swanson et al.,
2001). Generally, the stimulant treatments have been shown to be more effective than the
non-stimulants, however some patients are unable to tolerate stimulant side effects, while
patients with substance abuse co-morbidity may require the non-stimulant treatments to
prevent drug-primed relapse (Strange, 2008).
Methylphenidate has been used safely for about 50 years (Taylor et al., 2004) and has
been shown to be effective in improving working and visual memory (Wright and White,
2003; Rhodes et al., 2004), reading skills (Keulers et al., 2007), non-verbal and visual-
spatial learning (O’Toole et al., 1997; Bedard et al., 2004), academic performance (Yang
et al., 2004; McGough et al., 2006; Dommett et al., 2008) and in reducing hyperactivity
(Arnold et al., 1978; Posey et al., 2007). As a result, it is still one of the most commonly
prescribed drugs for the treatment of ADHD (Faraone et al., 2001), with decreasing age
of prescription onset (Kollins et al., 2006). Indeed, these cognitive enhancing effects of
methylphenidate are also experienced when used by healthy individuals (Elliott et al.,
1997), and illicit use by students to aid academic performance is common (McCabe et al.,
2006; Wilens et al., 2008). However, methylephenidate is not consistently effective (Ad-
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vokat, 2010). Some studies report that 68% of the ADHD treated group were considered
responders (Spencer et al., 2005), other studies have reported only 21% responders (Green-
hill et al., 2006) and a recent study reported that 15% of ADHD subjects dropped out of
the study due to lack of efficacy (Bejerot et al., 2010). Methylphenidate was shown to be
ineffective in elderly healthy volunteers (Turner et al., 2003), and although young healthy
individuals showed improvements in various cognitive aspects (Elliott et al., 1997), there
is high variability in response to methylphenidate that could in part be due to differ-
ences in dopamine tone between individuals (Volkow et al., 2002a). A rodent study found
that dopamine D4 receptor knock-out (KO) mice showed increased glucose metabolism
in the pre-frontal cortex (PFC), while homologous D4 positive and heterozygot mice had
decreased glucose metabolism in the PFC, and thus proposed a genetic explanation for
the differential response to methylphenidate (Michaelides et al., 2010). PET scans of
methylphenidate’s effects on DAT blockade and DA release showed that a 60 mg dose of
methylphenidate blocked 60±11% of DAT, and also caused a 16±8% increase in extra-
cellular DA levels in healthy individuals, however the DAT blockage and DA release were
not correlated (Volkow et al., 2002b). Thus Volkow et. al suggest that the individual
difference in response to methylphenidate could be due to individual differences in DA
release (Volkow et al., 2002b; Forssberg et al., 2006; Swanson and Volkow, 2009).
The mechanisms underlying methylphenidate’s therapeutic actions are heavily re-
searched but as yet unclear. It is a known dopaminergic and noradrenergic reuptake
blocker, with higher binding affinities for the norepinephrine transporter (NET) than
dopamine transporter (DAT) (Markowitz et al., 2006). Human positron emission tomog-
raphy (PET) studies with use of [11C]-raclopride binding displacement measures have
shown that oral administration of therapeutic doses of methylphenidate increased levels
of dopamine in the striatum of both normal subjects (Volkow et al., 2001), and those
with ADHD (Rosa-Neto et al., 2005), although the level of increase was lower in adults
with ADHD than controls (Volkow et al., 2007b). This increase in striatal dopamine
levels was also observed in a similar study performed in rodents and primates (Schiffer
et al., 2006). Norepinephrine levels in the brain were also increased with methylphenidate
treatment (Kuczenski and Segal, 1997, 2001). A whole-cell patch clamp study showed
that methylphenidate increased intrinsic excitability of prefrontal cortical neurons that
was mediated via the α2-adrenoreceptor (Andrews and Lavin, 2006), and support a be-
havioural study that showed improvement in the performance of a delayed alternation task
in rats through actions of α2-adrenoreceptor and dopamine D1 receptors in the PFC (Arn-
sten and Dudley, 2005). Since methylphenidate is generally effective in treating ADHD
symptoms, this evidence strongly implicates the involvement of both the dopaminergic
and the noradrenergic systems in ADHD aetiology.
Although generally effective, the side effects of stimulants are not tolerable in some
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patients, especially those with tic disorders or at risk of substance abuse or relapse (Sc-
ahill et al., 2001; Brennan and Arnsten, 2008), and alternative medications have received
much research attention (Glazer, 2010). It was initially shown that clonidine, a general
noradrenergic agonist, produced beneficial effects in the treatment of ADHD symptoms
with fewer side effects than methylphenidate (Hunt et al., 1985, 1986; Hunt, 1987). Sub-
sequently, guanfacine was also shown to be effective in treating ADHD symptoms in
children (Horrigan and Barnhill, 1995) and since it is less hypotensive, less sedating and
has a longer half-life than clonidine, guanfacine became prefered over clonidine for the
treatment of ADHD symptoms (Horrigan and Barnhill, 1995; Jakala et al., 1999a; May
and Kratochvil, 2010).
Guanfacine is a selective α2A-adrenoreceptor agonist (Scholtysik, 1986; Uhlen and
Wikberg, 1991a,b) that has been FDA approved for the treatment of hypertension since
1986 (Nakamichi et al., 1988; Horrigan and Barnhill, 1995). Guanfacine (0.6 mg/kg) in
a rat model of ADHD showed improvements in sustained attention and reduced hyper-
activity and impulsiveness (Sagvolden, 2006). Low or high doses of guanfacine improved
the performance of aged monkeys in the delayed-response task (Rama et al., 1996), while
a high dose of guanfacine (0.1 mg/kg) improved reversal learning performance in aged
rhesus monkeys (Steere and Arnsten, 1997). In humans, guanfacine was shown to im-
prove planning and working memory performance (Jakala et al., 1999a) as well as paired
associates learning (Jakala et al., 1999b) in healthy volunteers. A double-blind placebo
controlled study found that guanfacine and dextroamphetamine displayed similar efficacy
levels in adults with ADHD (Taylor and Russo, 2001), and that guanfacine was effective
and safe to use for 24 months without intolerable adverse effects (Faraone and Glatt,
2009; Biederman et al., 2008a,b; Posey and McDougle, 2007). Thus, guanfacine has been
recently approved by the FDA (September, 2009) for the treatment of ADHD (May and
Kratochvil, 2010).
The selectivity of guanfacine for the α2A-adrenoreceptor (Jarrott et al., 1982; Scholtysik,
1986) was highlighted by a rodent study where it improved spatial working memory of wild
type and α2C-adrenoreceptor KO mice, but not of α2A-adrenoreceptor KO mice (Franow-
icz et al., 2002). Stimulation of α2A-adrenoreceptors was found to inhibit cAMP signalling
in the post-synaptic spines of PFC neurons (Wang et al., 2007). Increased cAMP levels ac-
tivate Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels (Shin et al.,
2004) and decrease membrane resistance, while inhibition of cAMP closes HCN channels
and increases membrane resistance (Wang et al., 2007). An increase in membrane resis-
tance in the dendritic spines of PFC neurons would strengthen signal input by preventing
the dissipation of regional potential difference, and since HCN channels were co-localized
with α2A-adrenoreceptors in the dendritic spines of PFC neurons (Wang et al., 2007),
Arnsten et al. hypothesize that guanfacine improves working memory function through
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the inhibition of cAMP and HCN channels, that is mediated by the stimulation of α2A-
adrenoreceptors (Wang et al., 2007; Brennan and Arnsten, 2008), and strongly supports
the involvement of the noradrenergic system in the aetiology of ADHD.
Since both methylphenidate and guanfacine have shown degrees of efficacy in treating
ADHD symptoms, including that of hyperactivity (Taylor et al., 2004; Minzenberg and
Carter, 2008; Biederman et al., 2008b; Sagvolden, 2006) and do so via different hypoth-
esized neural mechanisms, we chose to focus the study on the effects of methylphenidate
and guanfacine on voluntary running in an animal model of ADHD, the SHR.
1.3 Genetic Associations
Familial and adoption studies have found that ADHD is highly heritable (Faraone and
Doyle, 2001; Biederman, 2005; Albrecht et al., 2010). Although attempts to determine
the causal genes for this disorder are extensive, findings from genetic studies to date have
been inconsistent (Banaschewski et al., 2010). The only concensus is that ADHD is a
heterogenous disorder with a complex genetic architecture, and that the overall phenotype
is likely due to multiple interacting genes, each with small effects (Smalley, 1997; Bobb
et al., 2005b; Faraone et al., 2005; Curatolo et al., 2008; Durston et al., 2009).
Given the mechanisms of the drugs that are successful in the treatment of ADHD,
many candidate gene studies are based on the hypothesis of the involvement of the
dopaminergic, noradrenergic and serotonergic systems.
Genes in the dopaminergic system associated with ADHD, include the 9 or 10 re-
peat alleles of the 3’-untranslated region (3’UTR) variable number of tandem repeats
(VNTR) of the DAT1 (SLC6A3) (Dresler et al., 2010; Bellgrove et al., 2008), dopamine
β-hydroxylase (DBH), dopamine receptor type 4 (DRD4) 7-repeat allele (Gornick et al.,
2007) and the dopamine receptor type 5 (DRD5) (Bobb et al., 2005b; Faraone et al., 2005;
Barkley et al., 2006; Lasky-Su et al., 2007). The DRD5 marker has in fact been linked
more specifically to ADHD-I and ADHD-C (Lowe et al., 2004). Studies have also reported
associations with adrenergic genes (Comings et al., 2000), particularly the NET1 (Bobb
et al., 2005a; Kim et al., 2008). Recent genome-wide association scans have additionally
implicated the α1A- and β2-adrenoreceptors (Lasky-Su et al., 2008), while a polymorphism
(C-1291G) in the promoter region of the α2A-adrenoreceptor gene has been linked specif-
ically to the ADHD-I subtype (da Silva et al., 2008; Kiive et al., 2010). A population
based study with samples of twins associated monoamine oxidase A (MAO-A) and sero-
tonin transporter (5-HTT) genes and platelet MAO-B activity with disruptive behavior
scores in adolescents (Malmberg et al., 2008), implicating serotonergic involvement.
Genes involved in general neural development and signalling have also been implicated,
for example a microsatellite in the synaptosome-associated protein of 25 kDa (SNAP-25)
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(Mill et al., 2005b; Zhang et al., 2010) was found to have weak associations in a linkage
study. An association study of 10 genes which encode neurotrophic factors (NTFs) and
their receptors in both adult and child ADHD produced data which suggested that vari-
ations in NTFs may be involved in the genetic susceptibility to ADHD (Ribases et al.,
2008). The study also suggested NTF-3 and neurotrophic receptor kinase 2 (NTRK2)
to be involved in the molecular basis of the age dependent changes in ADHD symp-
toms throughout the life span of the patient, and further support the contribution of the
cytokine neurotrophic factor receptor (CNTFR) locus as a predisposition factor for the
disorder (Ribases et al., 2008). NTF-3 is involved in the differentiation and survival of
dopaminergic and noradrenergic neurons and has been further implicated in a preliminary
case-control family-based Korean study (Cho et al., 2010). Among others, the cadherin-
13 (CDH13), brain derived neurotrophic factor (BDNF) and catechol-O-methyltransferase
(COMT) were also found to be significantly associated candidate genes in more recent
genome wide association studies (Lasky-Su et al., 2008), and thus new avenues of research
for the genetic causes for ADHD have been suggested (Banaschewski et al., 2010).
In addition to genetic factors, environmental factors such as maternal smoking (Mil-
berger et al., 1996), lower maternal folate status (Schlotz et al., 2010), early exposure
to polychlorinated biphenyls (PCBs) (Kuehn, 2010; Sagiv et al., 2010) and higher serum
levels of manganese (Farias et al., 2010) have been associated with the development of
ADHD. Indeed, there is certainly evidence that gene × environment interactions have a
highly relevant role in the development of ADHD. A study of the interaction between
maternal smoking and the 10 repeat allele of the 40 bp VNTR in the DAT1 gene showed
that children that were homozygous for the 10 repeat allele had increased symptoms of
hyperactivity, impulsivity and oppositional behaviour only if they were exposed to pre-
natal smoking (Kahn et al., 2003). A study of the interaction between the C-1291G
polymorphism in the α2A-adrenoreceptor gene and family maltreatment on 429 children
showed that while the boys with the CC genotype and low maltreatment scores showed
less overactivity than G allele carries, CC genotype boys with higher maltreatment scores
were more overactive, and more inattentive (Kiive et al., 2010).
ADHD is diagnosed on the basis of behaviour. Whether a subject participating in a
scientific study is grouped as ‘ADHD’ or ‘control’ is determined by behaviour. A hypo-
thetical subject with a predisposing homozygous 10 repeat allele in the DAT1 VNTR may
not have had pre-natal exposure to maternal smoking and thus be grouped as ‘control’,
while another hypothetical subject with the same genotype could be grouped as ‘ADHD’
if he was pre-natally exposed to maternal smoking. Results from such a study would
find no linkage of ADHD with this gene. In fact, genetic linkage and association stud-
ies differ in whether they control for the exposure to certain environmental factors (e.g.
maternal smoking), gender, co-morbidity, method of recuitment and age (Banaschewski
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et al., 2010), each of which could alter the subjects’ behaviour and significantly influence
the results. Further study of gene × environment effects on the aetiology of ADHD has
the potential to explain the discrepancy between studies regarding the causal genes of
ADHD (Banaschewski et al., 2010). However, gene × environment interaction research
is a highly complex field, and current statistical approaches are not equipped to handle
this complexity (Banaschewski et al., 2010). Once these challenges have been overcome,
gene × environment studies, along with more controlled genetic studies would provide
more valuable insights into the aetiology of ADHD, which may provide strategies for
individualized prevention and therapy (Wermter et al., 2010).
1.4 Structural Alterations
Volumetric anatomical studies of brain structures have identified the PFC (Castellanos
et al., 1996; Makris et al., 2007), caudate nucleus (CN) (Tremols et al., 2008), striatum
(ST) (Castellanos et al., 1994, 1996; Tremols et al., 2008; Buitelaar et al., 1996), substan-
tia nigra (Romanos et al., 2010), corpus callosum (CC) (Luders et al., 2009), hippocampus
(Plessen et al., 2006), anterior cingulate (Makris et al., 2010), cerebellar vermis (Castel-
lanos et al., 2001) and pulvinar nucleus in the thalamus (Ivanov et al., 2010) as regions
of defect in ADHD.
Cortical networks that support attention and executive function were found to be
thinner in adults with ADHD (Makris et al., 2007). In particular, there was bilateral
cortical thinning in the orbital frontal cortex, lateral superior and middle frontal gyri.
Right cortical thinning occurred in the angular gyrus, supramarginal gyrus and anterior
cingulate cortex. Left cortical thinning occurred in the posterior cingulate cortex (Makris
et al., 2007).
Inter-hemispheric connections are required to sustain attention and motor control
(Weber et al., 2005; Tassinari et al., 1994). An MRI comparison of the CC between ADHD
and control subjects confirmed the CC to be significantly thinner in ADHD subjects in
the anterior, but particularly the posterior callosal sections (Luders et al., 2009). The
decreased callosal thickness could be caused by decreased myelination of the axons, or
decreased number of fibers that connect the parietal and prefrontal cortices. Impairment
or lack of inter-hemispheric connections may contribute to the symptoms of ADHD. These
callosal abnormalities may be due to maturational delays, as many symptoms of ADHD
dissipate as the subject age increases, however, it has been found that 70% of those
diagnosed with childhood ADHD continue to have adult ADHD (Biederman, 1998), which
suggests that these abnormalities in the CC could be permanent (Luders et al., 2009).
Defects in visuospatial memory and temporal processing in individuals with ADHD
(Bedard et al., 2004; Barkley, 1997) have implicated the limbic system. An MRI study
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of hippocampus and amygdala morphology found that the head of the hippocampus was
bilaterally larger in the ADHD group compared to the control group (Plessen et al., 2006).
This study suggested that the enlargement of the hippocampus may be a compensatory
response to the disturbance in time perception and delay aversion in ADHD subjects
(Plessen et al., 2006).
Another MRI study found ADHD patients to have decreased right caudate body vol-
ume, as well as an inverse asymmetry of the caudate body and head as compared to the
controls. ADHD patients had a larger right caudate head volume than the left, and a
larger left caudate body volume than the right (Tremols et al., 2008). This newer study
suggested that a previous (less advanced) MRI study had found a larger right caudate
volume (compared to left caudate) in ADHD subjects (Hynd et al., 1993) because detailed
distinctions between caudate body and caudate head had not been made, since the tech-
nique to do so accurately was not available at that time (Tremols et al., 2008). Regardless
of direction of striatal symmetry, abnormalities of the ST have been found in additional
cases (Castellanos et al., 1994, 1996; Mataro et al., 1997) and thus is a structure that is
clearly involved in the pathophysiology of ADHD.
The most recent high resolution structural MRI study used a technique that created
a ‘cytoarchitechnotic’ map of the thalamic surface based on cellular structure (Ivanov
et al., 2010). A comparison between control and ADHD subjects, in the degree to which
the ADHD surface needed to be stretched or shrunk, showed that ADHD subjects not on
medication had bilaterally smaller pulvinar nuclei, while those on medication were more
similar to normal subjects. Additionally, severity of hyperactivity was associated with a
decreased volume in the lateral nuclei of the thalamus, while severity of inattention was
associated with an increase in size of nuclei in the right medial-posterior thalamus (Ivanov
et al., 2010), and suggests that further developments in structural imaging, including func-
tional Magnetic Resonance Imaging (fMRI) and diffusion tensor imaging (DTI) studies
may well provide diagnostic signals for ADHD (Shaw, 2010).
The aetiology of ADHD is likely to be both genetic and developmental. Genetic
aberrations could be the sole cause of structural abnormalities, and poorly regulated de-
velopment of neuronal networks as a result of genetic dysfunctions could lead to functional
problems when specific activities (such as sustained attention) are required, which exhibits
as a behavioural symptom. However, neural compensations are known to solve functional
problems, afforded by the high plasticity of the brain. Indeed, there are degrees of severity
of ADHD symptoms, and individuals with ADHD are not completely unable to function,
or devoid of all faculties of attention (Taylor, 1998). Thus, the structural defects found
in the imaging studies could be that of the original genetic defect or the result of the
subsequent (although perhaps inadequate) neural compensations. Structural studies are
important for determining target areas to refine further studies, and could prove to be
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useful for diagnosis (Ivanov et al., 2010; Shaw, 2010), however the abnormalities could be
a cause or a compensation of the disorder.
The present project elected to study the ST since it was found to be an area of
defect in humans (Tremols et al., 2008) and has been the focus of many neurochemical
studies in our SHR model of ADHD (Russell et al., 1995; Heal et al., 2008). The ST
also fundamentally controls activity/hyperactivity (Tucker and Williamson, 1984), and
additionally, it is an area with extensive dopaminergic activity that would allow for the
most selective measurements of dopamine concentrations with use of carbon fibre in vivo
chronoamperometry (elaboration in Introduction section 1.7).
1.5 Animal Models
ADHD is a behaviourally diagnosed disorder, based on the presence of reported symptoms
from a detailed history of the patient, observations from the family and subjective reports
from school or other observers (Thapar and noz Solomando, 2008), thus accurate diag-
nosis is difficult and highly variable between practitioners (Fulton et al., 2009). This has
caused problems not only with identifying appropriate treatment measures for patients,
but also hampers scientific study of the disorder in humans, since comparative groups are
determined based on these variable behavioural diagnoses. The huge genetic variety of
human populations and practical impossibility to control for environmental confounding
factors further challenge the ability of human studies to distill specific information. Ad-
ditionally, and most importantly, current methods used to directly study specific details
of neurochemical function, basic cellular abnormalities, and their correlation to observed
behaviours can be highly invasive and unethical to perform in humans.
Animal models are advantageous in ADHD research because it is possible to breed
genetically homogenous animals, control the experimental environment easily and specifi-
cally, they have simpler nervous systems, more easily quantifiable behaviours and a greater
variety of interventions may be applied (Sagvolden et al., 2005). This allows for the de-
tailed research of various behaviours and the neurocorrelates thereof, in order to determine
the aetiology of ADHD (and other disorders).
A good animal model of ADHD must satisfy the requirements for face, construct and
predictive validities. Face validity requires that animal behaviour mimics the fundamental
characteristics of the people with the disorder, thus the animal must present symptomatic
behaviours such as hyperactivity, impulsivity and inattention. Construct validity requires
that the animal model conforms to the theoretical rationale of the disorder, and predictive
validity requires that the animal model be able to predict aspects of behaviour, genet-
ics and neurobiology in humans that were previously unknown (Sagvolden et al., 2005;
Willner, 1984).
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In order to confirm face validity of the animal models, their behaviour requires to be
comparable with that of ADHD. However, ‘impulsivity’, ‘inattention’ and ‘hyperactivity’
are difficult to determine accurately even with psychometric tests that are specifically
designed to measure these aspects of behaviour in children (Johansen et al., 2002). Thus,
these behaviours, in both humans and rats, need to be defined in ways that allow empirical
measurement and quanfication, in order to draw meaningful comparisons between the
studies.
The study of animal operant behaviour in response to a discriminating stimulus (e.g.
light cue) rather than respondant behaviour, in response to a direct stimulus (e.g. foot-
shock) was pioneered by Skinner in the 1930s (Hilgard, 1939). Skinner studied the pattern
of operant responses (lever presses) as a result of reinforcers (food), and discovered ‘laws’
that governed the operant behaviours in different reinforcing situations. After the pre-
sentation of a single reinforcement as a result of an operant response (lever press due
to spontaneous rat exploration), the pattern named ‘reflex’ was discovered, where lever
presses inevitably continued after it resulted in the presentation of a reinforcement. The
‘extinction curve’ was observed when the number and rate of lever presses decreased
over time if reinforcement was discontinued, and the ‘resistence to extiction’ was the
potential number of lever presses that would occur without further reinforcement. Rein-
forcement of the operant behaviour at periodic intervals (every 3, 6 or 12 mins) resulted
in a characteristically uniform rate of responding. Reinforcers presented in fixed ratios,
where reinforcement was presented every 10th, 20th or 192nd lever press, resulted in a
typical acceleration of responses (Skinner, 1938; Hilgard, 1939). The paradigms used to
measure behavioural patterns have since been refined and further developed in order to
measure additional and more complex behaviours empirically. In particular, the ‘delay-of-
reinforcement gradient’ is a behavioural pattern found where the shorter the time between
the operant response and reinforcement delivery, the higher the likelihood of the response
being performed again, and it was proposed that individuals with ADHD have steeper
and shorter delay gradients, which would explain the ADHD symptoms (Catania et al.,
1988; Sagvolden et al., 1998; Johansen et al., 2002).
The ‘inattention’ observed in ADHD is specifically a deficit in sustained attention
(Johansen et al., 2002), and appears to have a strong motivational component, since the
problem is revealed only when the task is unwelcome or uninteresting (Taylor, 1998). In-
dividuals with ADHD are able, at least temporarily, to maintain focus on tasks that are
interesting to them, ‘when the behaviour is maintained by potent and frequent reinforcers’
(Johansen et al., 2002). Sagvolden et. al proposed that the impairment in sustained at-
tention in ADHD should be more appropriately termed ‘cognitive impulsiveness’, and
measured as the inability to maintain refrain from lever pressing after the extinction of
reinforcements signaled by a discriminative cue (Sagvolden et al., 1992b; Johansen et al.,
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2002). Impulsiveness, or ‘motor impulsiveness’ is characterized by bursts of responses with
short inter-response times in a task with fixed interval schedule (where only 1 response
will be reinforced at regular intervals), especially during the interval when additional re-
sponses will not be reinforced (Sagvolden et al., 1998). In terms of hyperactivity, children
with ADHD have been shown to move twice as frequently, and cover a four fold wider
area, with body movements that are more linear (side-to-side) and less complex than
normal children (Taylor, 1998). Overactivity also occurs only after habituation, and not
in novel environments. In humans, movements really only become ‘hyper’ when implicit
or explicit social rules are overstepped, and depends on situational appropriateness, and
hyperactivity is often described in classroom situations but not in play (Taylor, 1998).
‘Social appropriateness’ of activity is not measureable in a rat, and the thinner cortical
structures in rodents compared to humans prevent detailed studies of top-down control
of behaviour. However quantities and patterns of activity in comparison with other ‘con-
trol’ rat strains can be measured in environments such as the the standard open field, or
other behavioural tests, in terms of total distance moved, and velocities or frequencies of
movements (Johansen et al., 2002).
The heterogeneity of the ADHD symptoms has been confirmed by the wide variety of ma-
nipulations in animals that can cause the presentation of some or all of the behavioural
symptoms of ADHD. While each experimental model provides valuable insight into var-
ious aspects of the disorder, animal studies of the symptoms of ADHD are extensive,
and a comprehensive review of each of the models is not practical for the purpose of this
dissertation. This section will thus review 3 models in detail, namely the Spontaneously
Hypertensive Rat (SHR), the dopamine transporter knock-out (DAT-KO) mouse and the
coloboma mutant mouse, and briefly mention the other proposed models of aspects of
ADHD, since they highlight the spectrum of possible causes for the disorder.
1.5.1 The Spontaneously Hypertensive Rat (SHR)
The spontaneously hypertensive rat (SHR) was originally selectively bred for hypertension
from the Wistar-Kyoto (WKY) rat strain (Okamoto and Aoki, 1963), however behavioural
studies in the late 70’s and early 80’s began to show that the SHR, usually in comparison
with the WKY or Wistar rat strains, showed higher levels of activity and lower levels
of anxiety in the open field test (Knardahl and Sagvolden, 1979; Danysz et al., 1983).
Much research has since been conducted on this rat strain, which has now become the
most well characterised animal model for ADHD (Russell, 2007). In fact, it is also the
most well characterised model for hypertension (Pravenec and Kurtz, 2010), and although
most details from the hypertension studies do not appear directly relevant to the ADHD
studies, it serves to bear in mind that there is much physiological data available on this
rat strain that could potentially provide better context and explanations for the results
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of the direct neural studies that are the focus of this subsection.
Initial open field tests found that the SHR showed hyperactivity in comparison with the
WKY gradually, after habituation to the environment (Knardahl and Sagvolden, 1979;
Sagvolden et al., 1993b), and that the number of lever presses in a reinforcement task
was higher in SHR compared to 4 other rat strains (Sagvolden et al., 1993b), which
provided promising face validity for hyperactivity. Investigations of the reinforcement
processes showed that the SHR had higher response rates to immediate reinforcements
than WKY, however when reinforcement delivery was delayed after the response, the num-
ber of responses from the SHR for the delayed reward decreased more sharply than for
WKY, although the number of SHR responses were higher than that for WKY (Sagvolden
et al., 1993b). The authors interpret these results as an indication of a steeper delay-of-
reinforcement gradient in the SHR compared to WKY, confirmed in a later experiment
that showed that SHR and WKY behaviour did not differ if reinforcements were given
immediately, however the responses of the SHR decreased more than that of WKY when
a delay between the response and reinforcer was introduced (Sagvolden et al., 1993a).
In response to methylphnidate, both the SHR and WKY showed increased numbers of
responses, however the delay-of-reinforcement gradient in both strains was decreased, and
the effectiveness of the delayed reinforcer was increased. This drug effect was less pro-
nounced in the SHR compared to WKY (Sagvolden et al., 1993b). Methylphenidate also
increased both SHR and WKY activity in terms of exploratory behaviour in the open field,
as well as in the operant chamber in a more recent visual stimulus position discrimination
task (Wultz et al., 1990; Thanos et al., 2010). Although sub-chronic methylphenidate
treatment decreased rearing activity of the SHR in the Làt-maze (Aspide et al., 2000).
In a differential low rate of reinforcement task (DRL), where the rat was required to
wait 1, 2, 5, 10, 20, 30 or 60s (DRL-1s ∼ DRL-60s) before pressing the lever in order
to receive the reinforcement, the performance of the SHR was not impaired compared
to the WKY or SDs. In fact, when high response rates were required (DRL-1s), the
WKY performed the most poorly in comparison to both SHR and WKY (Bull et al.,
2000). This study argued that the SHR did not exhibit excessive impulsivity, but that
the WKY showed a uniformly low response rate (Bull et al., 2000). Another study used
the DRL schedule to evaluate the performance of SHR, WKY and Wistar rats, found that
the SHR exhibited impulsivity during the acquisition phase of the experiment, however
higher doses of methylphenidate (4 and 8 mg/kg) impaired the performance of all three
rat strains. Impulsivity was exhibited by SHR during acquisition, but methylphenidate
impaired their performance in the task requiring response inhibition. The lack of efficacy
of MPH in this study suggested that the SHR may not be a reliable model for ADHD,
however it is also possible that the DRL protocol may not the optimum procedure for the
measurement of impulsivity (na et al., 2009).
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The α2A-adrenoceptor agonist guanfacine improved sustained attention and reduced
overactivity and impulsiveness in SHR in a multi Random Interval/Extinction procedure
where the correct lever press (signaled by a discriminating lever light over the lever) was
rewarded within 180s and an incorrect lever press was followed by an extinction schedule
(Sagvolden, 2006). A similar behavioural test showed that l -amphetamine improved poor
sustained attention while d -amphetamine reduced overactivity and impulsiveness as well
as improved sustained attention in SHR (Sagvolden and Xu, 2008).
In a spatial learning task using the Morris Water Maze, atomoxetine, a selective NET
blocker, improved spatial learning during the acquisition phase of the task, reflected in
decreased latency to reach the platform in treated animals. Spatial memory was also
improved as shown by increased amount of time spent in the target quadrant during the
probe trial in the treated animals compared to controls (Liu et al., 2008). This study also
measured increased histamine release in response to atomoxetine treatment and suggested
a strong histaminergic component for the improvement of spatial memory in treated SHR
(Liu et al., 2008). Unfortunately, no comparative strain was used in this study.
SHR neurotransmission has been studied extensively in vitro, especially via superfu-
sion experiments, in comparison with the WKY rat strain. It was found that electrically
stimulated [3H]DA release from the caudate putamen and PFC in SHR was lower than
that of WKY, while D2-autoreceptor function measured in response to quinpirole acti-
vation showed that DA release was significantly decreased in the caudate of the SHR,
but not in the PFC or NAc in comparison with the WKY (Russell et al., 1995). These
responses suggested that the SHR could have region specific sensitization of D2 autorecep-
tors in the caudate, but not in the PFC of the SHR (Russell et al., 1995). The increased
response to quinpirole was supported by higher D2 receptor mRNA expression in the
SHR striatum (Vaughan et al., 1999). Application of methylphenidate or d -amphetamine
stimulated [3H]DA release in the caudate, NAc and PFC of both SHR and WKY, al-
though the methylphenidate stimulated response was 7 ∼ 17 fold less potent than that of
d -amphetamine, and the amount of [3H]DA released from the NAc was lower in the SHR
compared to WKY (Russell et al., 1998). Electrical stimulation of [3H]DA release in the
presence of methylphenidate resulted in similar release levels in the SHR and WKY, while
the presence of d -amphetamine caused more DA release from SHR than WKY (Russell
et al., 1998). The difference in the mechanisms of drug action between methylphenidate
and amphetamine could explain the difference in DA release levels in the presence of each
drug. While both methylphenidate and amphetamine block the DAT and prevent reup-
take of DA, amphetamine additionally causes vesicle leakage of DA into the cytoplasm
by the reversal of vesicular monoamine transporter 2 (VMAT2) and DA release into the
synapse by reversal of the DAT. Thus, the similar responses between SHR and WKY in
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presence of low dose methylphenidate indicated that DAT function was not different be-
tween the strains, and is unlikely the source of the dopaminergic impairment in the SHR.
The ability of d -amphetamine to mediate increased DA release in SHR compared to WKY
suggested that the SHR had higher levels of DA in the cytoplasm of neurons that was
released by the reversal of DAT in the presence of d -amphetamine. Taken together, this
study suggested that the SHR may have impaired vesicular storage of DA (Russell et al.,
1998). Stimulated release of norepinephrine from PFC slices either electrically or with
potassium showed no difference between the SHR and WKY, however α2A-adrenoreceptor
mediated inhibition of norepinephrine was less effective in the SHR (Russell et al., 2000).
These results suggested that although there was no deficiency in the release of NE, the
inhibitory control of NE in SHR could be deficient (Russell et al., 2000).
Recently, an in vitro study of dopaminergic parameters in juvenile SHR and WKY
striatal synaptosomes showed similar results to the superfusion experiments in that up-
take rates of DA by DAT were not significantly different between the SHR and WKY
(Simchon et al., 2010). However, although basal DA release was lower in SHR, potas-
sium, amphetamine and methylphenidate stimulated release of DA were not significantly
different between strains (Simchon et al., 2010), which contrasts the superfusion studies
that showed increased amphetamine but not methylphenidate stimulated release in adult
SHR (Russell et al., 1998). Chronic methylphenidate treatment (21 days, i.p, 3 mg/kg)
in juvenile SHR caused decreased basal DA release compared to saline treated SHR, how-
ever potassium and amphetamine stimulated release was increased in the treated group
(Simchon et al., 2010). In a study of 1 month old SHR, DAT and TH expression were
found to be decreased compared to WKY (Leo et al., 2003). Measurement of DAT and
VMAT2 showed significantly lower densities in the SHR striatum (Simchon et al., 2010).
The lower VMAT2 densities support the previously suggested impairment of vesicular
storage (Russell et al., 1998).
Taken together, the in vitro studies have suggested a hypofunctioning dopaminergic
system and a hyperfunctioning noradrenergic system in the SHR (Russell, 2002; Russell
et al., 2005). The lower basal release of DA could be be due to a compensation for the
lower DAT densities in SHR, and the increased amphetamine induced release of DA could
be due to decreased VMAT2 densities, resulting in elevated amounts of DA in the cyto-
plasmic compartment of the presynaptic neurons (Simchon et al., 2010). However, DAT
densities were found to be higher in SHR compared to WKY in adult and juvenile rats,
and in addition, the D1 receptor was found to be increased in adult SHR caudate (Watan-
abe et al., 1997). Further studies and analysis of variations in experimental methods are
required in order to draw any conclusions from the various contradicting information.
In comparison to the number of in vitro neurochemical studies that have been per-
14
Animal Models Chapter 1. Introduction
formed on the SHR, in vivo studies have been surprisingly few, most of which have been
related to hypertension (Linthorst et al., 1991; Terrazzino et al., 1994; Miyamae et al.,
1995; Ferguson et al., 2003), and the results have been no less disparate.
Initially, in vivo microdialysis found that although basal DA levels were not different
between SHR and WKY, DOPAC levels were significantly lower in SHR than WKY in the
caudate of 8 week old rats (Linthorst et al., 1991). Administration of quinpirole showed
that the SHR had more responsive D2 autoreceptors, indicated by a stronger inhibition of
DA release, although DOPAC levels were similar between SHR and WKY after quinpirole
treatment (Linthorst et al., 1991). Likewise, basal dopamine levels in both the nucleus
accumbens and the ventrolateral striatum were lower in SHR than WKY rats, and levels
of dopamine in the nucleus accumbens (NAc) were lower than in the the ventrolateral
ST in both strains (Fujita et al., 2003). Infusion of quinpirole also showed that SHR had
more responsive D2 autoreceptors, particularly in the NAc, in comparison with the WKY
(Fujita et al., 2003). In terms of behaviour, this study co-administered quinpirole with the
D1 agonist SK-38393, which caused stereotypic jaw movements in WKY, but not in SHR,
and suggested that the postsynaptic D1 receptors are hyposensitive compared to WKY
(Fujita et al., 2003). An interesting measurement of tonic DOPA levels from the caudal
ventrolateral medulla (CVLM) showed that the SHR had lower tonic DOPA levels than
WKY (Miyamae et al., 1995). Injection of L-DOPA into depressor sites of the CVLM
decreased SHR hypertension and suggested that tonic neural activity to release DOPA in
the CVLM is lost in the SHR, which results in the maintainence of hypertension in SHR
(Miyamae et al., 1995).
Contradicting results however have been reported in 2 subsequent in vivo microdial-
ysis studies. Measurements taken from the NAc shell of 6 week old SHR showed signif-
icantly higher basal DA release compared to WKY, and low dose methylphenidate and
amphetamine stimulated higher levels of DA increase compared to WKY (Carboni et al.,
2003). Potassium stimulated release of DA was however lower in SHR compared to WKY
(Carboni et al., 2003), which could be explained by the apparent VMAT2 defect in SHR
impairing DA storage (Simchon et al., 2010). A comparison of SHR to the SD rat strain
showed similar patterns as those with WKY, where measurements of DA from the ST
were 78% higher in SHR than SD (Heal et al., 2008). Basal NE release measured from the
PFC was 26% lower in SHR than SD (Heal et al., 2008). Low dose amphetamine treat-
ment induced significantly higher levels of NE release from the PFC in the SHR compared
to SD, while only higher dose (9 mg/kg) amphetamine induced striatal DA releases that
were significantly larger than SD (Heal et al., 2008). An in vivo microdialysis study in
SHR without strain comparison showed that atomoxetine treatment (2 mg/kg, i.p) sig-
nificantly increased cortical NE, DA and histamine, that was correlated with improved
spatial learning (Liu et al., 2008).
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The shortcomings of in vitro studies lie largely in that neuronal sections have been
taken out of context and the study of longer loop network effects are not possible. In vivo
microdialysis is able to take highly accurate measurements of neurotransmitter concen-
trations from the most relevant context in a freely-moving animal, however it has poor
spatial and temporal resolution. It is possible that more modern techniques of in vivo
microdialysis in the latter studies could provide more accurate information than the pre-
vious microdialysis studies, however, a detailed review of microdialysis method refinement
does not fall within the scope of this dissertaion. At this time, no in vivo voltammetric
studies in SHR have yet been published. The present project will thus present novel data
on the measurement of DA release and uptake in SHR, at a higher spatial and temporal
resolution than can be studied by microdialysis.
Neurotransmission in the striatum and PFC have been studied extensively in the SHR,
and age related changes have been found. Recently, micrographs of Nissl-stained striatal
serial sections measured striatal volume of SHR compared with WKY at weekly intervals
between 4 ∼ 10 weeks old (Hsu et al., 2010). It was found that the striatum was signifi-
cantly smaller in the SHR compared to WKY only at 5 weeks of age (equivalent to 7∼9
years in humans (Quinn, 2005), but not in the subsequent ages, and suggested that abnor-
malities in the striatum for ADHD occurs at the prepubertal stage (Hsu et al., 2010). The
lack of size difference in the ST in subsequent ages also suggests that the developmental
defect that was detectable at 5-weeks was rectified via compensatory mechanisms until it
is no longer structurally detectable by the Nissl-stained method. Although neurochemical
studies show clear evidence of altered function.
Dendritic morphology of neurons in medial prefrontal cortex, hippocampus and nu-
cleus accumbens were studied at 2, 4 and 8 months of age in SHR, campared to WKY
with use of the Golgi-Cox stain and Sholl analysis (Sanchez et al., 2010). At 4 and 8
months, the SHR showed decreased spine density in pyramidal neurons from the mPFC
and in medium spiny cells from the NAc. At 8 months, the pyramidal neurons from the
hippocampus exhibited a reduction in the number of dendritic spines (Sanchez et al.,
2010).
It has been suggested that the impaired metabolism (Doroshchuk et al., 2004) and Ca2+
regulation (Fellner and Arendshorst, 2002) in SHR could be the basis of many SHR de-
fects, including that of hypertension. Higher intracellular Ca2+ levels would decrease the
Ca2+ gradient across the neuronal membrane and could impair Ca2+ dependant neuronal
function (Russell, 2007). This hypothesis is interesting, since the SNAP-25 defect in the
coloboma mouse impairs its calcium regulated neurotransmission, which has been related
to their spontaneously hyperactive behaviour (below).
Considerable concern has been attributed to the possible confounding effect of hyper-
tension on results of the neurochemical studies on the SHR. In fact, more recent studies
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have made concerted efforts to study the SHR at the pre-pubertal stage as opposed to the
adult stage, since more sever hypertension develops between 6 ∼ 10 weeks of age inthe
SHR, and only mild hypertension is present in SHR at 4 weeks of age (van den Buuse
and de Jong, 1988). An in vivo microdialysis study had in fact suggested that increased
sensitivity of D2 autoreceptors in SHR but not salt induced-hypertensive rats suggested
that the alterations in the nigrostriatal DA system could be involved in the initiation of
the development of spontaneous hypertension (Linthorst et al., 1991).
Genetic fingerprinting of SHR in 1991 had shown that SHR stocks between the NIH and
the Shimane Institute of Health Science in Japan were substantially different genetically,
especially in the substrain of stroke-prone SHR, while the NIH and Charles River SHR
stocks differed only slightly (Nabika et al., 1991). Various substrains of both the SHR
and WKY have been selectively bred for specific characteristics, e.g the WKY/HA sub-
strain is hyperactive but not hypertensive, while the WKY/HT substrain is hypertensive
but not hyperactive (Sagvolden, 2000). Studies between substrains have been useful to
determine that the neurobiology of hyperactivity was not a result of hypertension. A
more recent comparison of SHR and WKY stock from various sources found that the
genetics of the WKY from New Charles River Germany (WKY/NCrl) and WKY from
Harlan UK (WKY/NHsd) had diverged by 33.5% and that the WKY/NCrl is a good rat
model for ADHD-I when measures of attention were shown to be impared in this substrain
compared to WKY/NHsd and Sprague Dawley rats from Taconic, US (SD/NTac). Thus
comparisons between the SHR from New Charles River (SHR/NCrl) with the WKY/NCrl
as controls would be inappropriate. In addition, the SD/NTac and the WH/HanTac rats
show significant genetic and/or behavioural differences from WKY/NHsd rats and appear
not to be appropriate controls in studies using the SHR/NCrl (Sagvolden et al., 2008),
since comparisons between genetically more similar strains and substrains that have diver-
gent behaviours would provide a narrower focus in determining the origin of the specific
behavioural difference (Sagvolden et al., 2009).
The genetic basis of the SHR behavioural deficits are not known. Gene sequencing of
the D2, D4 and DAT1 genes showed that the SHR had several variations of the DAT1
gene which was found to be different from the that of the WKY, although no differences
in the D2 or D4 receptors were found (Mill et al., 2005a). This finding supports the hu-
man linkage and association studies of the DAT gene to ADHD and provides additional
support for the model.
Thus, although much disagreement exists in the results of the SHR studies regarding
the neural basis of its undisputed hyperactive behaviour, and variably defined inattention
and impulsivity, discrepancies due to differences in methodical approach and comparative
strain selection between laboratories is possible, but also determinable by further study.
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Research since the early 90’s had found the SHR to conform to all three validation criteria
for a good animal model for ADHD (Sagvolden et al., 1992b), and the SHR is still the
strain of choice for the study of ADHD (Russell, 2007), and was utilized in the present
study.
1.5.2 The Dopamine Transporter Knock-Out mouse
Since psychostimulant treatment blocks DAT activity, increases striatal DA and decreases
locomotive hyperactivity, it serves to study DAT activity, or the effects of the lack thereof,
in more detail. The DAT-KO mouse is relevant because it exhibits behavioural charac-
teristics that include hyperactivity and impaired learning and memory (Gainetdinov and
Caron, 2001), especially in terms of cognitive inflexibility, shown by their impaired extinc-
tion of responses in an operant food reinforcement task (Hironaka et al., 2004). Although,
this mouse model also exhibits stereotypic behaviours which are more characteristic of
Tourettes syndrome and obsessive compulsive disorder, and its exhibition of hyperactiv-
ity occurs predominatly in a novel environment, which contradicts the human behaviour
where hyperactivity occurs after environmental habitutation; and is not an ideal animal
model for ADHD (Berridge et al., 2005; Russell et al., 2005). However, the DAT-KO
mouse provides much valuable insight into the consequences of the extreme loss of DAT
and the hyperdopaminergic state, and provides highly relevant comparative data.
In vivo microdialysis of freely moving DAT-KO animals showed that the basal level
of DA is at least 5 times higher than in wild type mice, while cyclic voltammetric mea-
sures in striatal brain slices showed that these persistently hyperdopaminergic mice had a
300-fold slower clearance rate of DA from the extracellular space and were also found to
have a 75% decrease in amplitudes of electrically evoked dopamine release (Jones et al.,
1998). Without DAT-mediated dopamine recycling, these mice synthesize new DA con-
tinuously, as shown by a complete elimination of DA from the striatum of the mice when
tyrosine hydroxylase (TH) was inhibited with use of α-methyl-para-tyrosine, and explains
the low DA releasing abilities of the striatal neurons (Volkow et al., 1996). Inhibition
of of DA synthesis in this experiment also showed that the behavioural hyperactivity
exhibited by these mice is mediated by the hyperdopaminergic state in the striatum,
since the DA depletion also reversed their hyperactive behaviour (Volkow et al., 1996).
The hyperdopaminergic state essentially abolished autoreceptor function, shown by the
inability of quinpirole (D2 autoreceptor agonist) to reduce dopamine levels in DAT KO
mice, while significantly depleting extracellular dopamine in wild type mice in vitro and
in vivo (Jones et al., 1999). Additionally, D1 and D2 receptors were downregulated by
approximately 50% in the ST of the KO mice (Giros et al., 1996). Immunodetection of
the the D1 receptor in these mice showed that their trafficking to the plasma membrane
and dendrites was reduced by 52% and 40%, respectively, and that the receptors showed
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increased accumulation in the endoplasmic reticulum and golgi bodies at 95% and 131%
respectively, compared to wild type mice (Dumartin et al., 2000).
The increase of dopamine availability with the use of methylphenidate to block DAT
decreases symptoms of hyperactivity in ADHD, and it would seem paradoxical that the
higher tonic dopaminergic levels in the DAT-KO mice would exhibit hyperactivity. How-
ever, the balance of dopamine in the brain is crucial in the ability to exert motor control
(Kuhar, 1992). In cases of psychostimulant abuse where dopaminergic levels increase sub-
stantially more than that of treatment dosages of methylphenidate, hyperactivity is also
observed (Kuhar et al., 1990; Inada et al., 1992). Hyperdopaminergia caused the expected
downregulation of D1 and D2 receptors (Giros et al., 1996; Dumartin et al., 2000), how-
ever this compensation appears inadequate for normalizing the behavioural hyperactivity
observed (Gainetdinov et al., 1999).
The DAT is a key protein involved in direct dopaminergic regulation, which is likely
to be impaired in ADHD. Additionally, human genetic linkage and familial studies have
associated various polymorphic alleles of the DAT1 gene to ADHD (Mill et al., 2005b;
Bobb et al., 2005b; Dresler et al., 2010), and strongly support further study of the DAT.
1.5.3 The Coloboma (Cm) SNAP-25 mutant mouse
The coloboma mice carry a heterozygous deletion mutation on chromosome 2 that includes
a sequence of the SNAP-25 gene, and was shown to exhibit characteristic ‘head-bobbing’,
small eyes and profound spontaneous hyperactivity, compared to their wild type coun-
terparts (C3H/HeSnJ) (Hess et al., 1992). Since the coloboma mutation was induced by
neutron irradiation that caused a deletion of approximately 2×106 bp, or between 30 ∼
50 genes, the coloboma phenotype likely arises from several of the affected genes (Hess,
1996). However, the hyperactive behaviour was attributed specifically to the deletion of
the SNAP-25 gene by an elegant trangenic study (Hess et al., 1996). Hess et. al first
showed that the coloboma mutants were 3∼4 times more active than wild type, and
that this hyperactivity was ameliorated by low dose (2 or 4 mg/kg, s.c.) d -amphetamine
treatment, while amphetamine had no effect (2 mg/kg) or increased locomotor activity (4
mg/kg) in wild type mice. Stereotypic behaviour occured in both mutant and wild type
mice when higher doses (8 and 16 mg/kg) of amphetamine were used. Methylphenidate
treatment (2∼32 mg/kg) however increased locomotor activity in both the mutant and
wild type mice. Transgenic mice that over expressed SNAP-25 were then created, and
cross bred with the coloboma mice. The results showed that the SNAP-25 expressing
transgene normalized the activity in the coloboma mutants, without affecting the head-
bobbing or opthalmic deformation (Hess et al., 1996). This work identified the SNAP-25
protein to be involved in the control of motor activity.
SNAP-25 is a peripheral membrane protein involved in the anchoring of vesicles to the
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presynaptic terminal membranes of neurons, and assists in the Ca2+-dependant exocytosis
of neurotransmitters (Kandel et al., 2000). SNAP-25 appears necessary for neurotransmit-
ter release in all CNS neurons, however highest expression levels appear in the neocortex,
piriform cortex, hippocampus, nuclei in the anterior thalamus, pontine nuclei, substantia
nigra and cerebellar granule cells (Oyler et al., 1989).
An initial in vitro study of cortical, dorsal striatal and ventral striatal slices showed
that KCl stimulated release of DA from coloboma tissue slices was inhibited in the dorsal
ST but not in the NAc, and was greater in the cortex compared to stimulated wild type
slices, although basal release of DA was similar to wild type mice (Raber et al., 1997). The
study also showed diminished stimulated release of 5-HT from in the dorsal striatum, but
no difference in the NAc or cortex, and similar basal release levels compared to wild type.
Additionally, stimulated glutamate release from cortical synaptosomes, as well as total
glutamate content were significantly lower than that of wild type (Raber et al., 1997). It
was thus demonstrated that the coloboma mutants exhibit region-specific and selective
neurotransmitter deficiencies and suggested that there could be differential requirements
for SNAP-25 in different neurons for the release of particular neurotransmitters (Raber
et al., 1997), since the mutants have 50% less SNAP-25 mRNA expression in the whole
brain (Hess et al., 1992). The DA metabolites HVA and DOPAC, measured by HPLC,
were significantly lower in the NAc, and showed a trend to be lower in the ST of mutant
mice. DA levels also showed trends to be lower in both the ST and NAc, while NE
was significantly higher in both the ST and NAC, compared to wild type (Jones et al.,
2001). These results supported that this mouse maintained a hypodopaminergic and
hypernoradrenergic state.
A later in vivo microdialysis study showed that the mutant mice had basal DA con-
centrations that were at least 80% higher than the controls (Fan and Hess, 2007). This
high basal dopaminergic tone was attributed to excess release and not impaired reuptake,
indirectly measured by comparisons of the microdialysis extraction fractions between the
mutants and controls, which is paradoxical considering the SNAP-25 deletion. Addition-
ally, amphetamine stimulated release in the striatum was higher in the mutants, even
after controlling for the basal release levels (Fan and Hess, 2007), contradicting the in
vitro studies previously performed by the same group (Hess et al., 1992). The 2007 study
focused on the ability of raclopride to inhibit the ability of amphetamine to decrease hy-
peractivity in the mutants, as well as the ability of amphetamine to increase the activity of
controls, and showed that D2-like receptors in the mutants were hypersensitive and more
effective at inhibiting cAMP levels (Fan and Hess, 2007). The most recent work by this
group showed that additional deletion of the D2 gene from the mutant mice normalized
both their hyperactivity and basal dopaminergic levels and targets the D2 (but not D3
or D4) receptor for mediating the hyperactivity of this mouse (Fan et al., 2010).
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The hypernoradrenergic state was confirmed by an in vitro superfusion study that
showed the mutants had at least 35% greater NE release from striatal and NAc slices,
while DA release in the same region was comparable to that of wild type mice (Jones
and Hess, 2003). Depletion of NE with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine
hydrochloride (DSP-4) (i.c.v.) from mutant mice was then shown to be effective in reduc-
ing hyperactivity (Jones and Hess, 2003). Specifically, antagonists to the α2C-adrenergic
receptor reduced hyperactivity in mutant mice, while antagonists of other adrenergic
receptors had little effect (Bruno et al., 2007). These experiments implicate a strong
noradrenergic contribution to the hyperactivity of these mice.
Besides spontaneous hyperactivity, the coloboma mice also display evidence of inat-
tention, as determined by impaired inhibition in a delayed reinforcement task, and im-
plulsivity, as determined through a delayed reinforcement task, of which inattention, but
not impulsivity, could be reduced by DSP-4 treatment (Bruno et al., 2007).
Although much research has been performed on the coloboma mouse, the neurochem-
ical basis for its behavioural symptoms have yet to be elucidated. The authors describe
the ability of amphetamine but not methylphenidate to decrease hyperactivity in these
mice as ‘paradoxical’ (Hess et al., 1996), however the difference between amphetamine and
methylphenidate mechanisms of action in synaptic terminals was not compared. While
both methylphenidate and amphetamine inhibit DAT function, amphetamine has the ad-
ditional ability to cause DA release through reversal of DAT and VMAT2. This difference
in drug mechanism is important in a SNAP-25 mutant, since amphetamine would be able
to cause a release of DA from terminals through the reversal of DAT, while the inhibition
of DAT by methylphenidate would cause a much milder increase in DA levels, by only
slowing reuptake. Additionally, methylphenidate, even at low dose, has been shown to
increase rodent activity. However, the in vivo microdialysis results that show higher basal
DA releasing levels is paradoxical as compared to the in vitro studies, and considering
the heterozygot SNAP-25 deletion. The authors hypothesize that the high extracellular
dopamine in vivo could result from impaired GABA release due to the SNAP-25 defect,
which leads to the disinhibition of the dopaminergic neurons that is not relevant in the in
vitro studies, which show diminished release from striatal slices when measured directly
(Fan et al., 2010).
Thus it appears that the coloboma mouse exhibits both hyperdopaminergia, as well
as hypernoradrenergia. And while decreasing NE reduces hyperactivity and improves at-
tention, a further (although moderate) increase in DA also decreases hyperactivity. Since
the D2 receptor was found to be hypersensitive in the mutants, perhaps the increase in
DA from amphetamine treatment decreased hyperactivity because of elevated D2 effects,
while the wild type mice showed increased activity due to increased activation of the D1
receptor.
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Along with construct validity from the efficacy of amphetamine treatment, genetic as-
sociations have linked a microsatellite in the SNAP-25 with hyperactivity in ADHD (Mill
et al., 2005b). Although more extensive characterization of the impulsive and inattentive
behaviours are required to determine a wider relevance of this model for ADHD aetiology,
it is already evident that, further study of this animal model will provide valuable insight
into the neural mechanisms that mediate the spontaneous locomotor hyperactivity in this
model that is highly relevant for ADHD.
Additional manipulations have also caused presentations of symptoms of ADHD will
not be elaborated upon. Briefly, prenatal exposure to alcohol produced defects in dopamin-
ergic neurotransmission, attention deficit and hyperactivity (Hausknecht et al., 2005).
Anoxia in the neonatal rat produced alterations in monoaminergic neurotransmission, spa-
tial memory impairment and transient hyperactivity (Lou, 1996). Neonatal 6-hydroxydopamine
(6-OHDA) lesioned rats displayed impaired learning in a spatial discrimination task and
hyperactivity, but not impulsivity, which could be reduced by dopamine D4 receptor
antagonists, as well as NET and 5-HTT inhibitors (Davids et al., 2003). Male trans-
genic mice that express a human mutant thyroid receptor in the pituitary (TRβ1) dis-
played symptoms of inattention, hyperactivity and impulsivity, which could be reduced
by methylphenidate (Siesser et al., 2006). The deletion of the β2-subunit of the nicotinic
acetylcholine receptor caused mice to display inattention, impulsivity and hyperactiv-
ity (Granon and Changeux, 2006; Russell, 2007). Mice that were prenatally exposed to
nicotine displayed spontaneous locomotion that could be reduced by agonists to the α4β2-
nicotinic receptor (Granon and Changeux, 2006). Poor performers in the 5-choice serial
reaction time (5-CSRT) test selected from Wistar rats have been put forward as a model
for impulsiveness and deficient sustained attention, but not hyperactivity (Puumala et al.,
1996).
In all, animal models have provided much, although as yet unexplainable contra-
dictions regarding the possible aetiology of ADHD. The dopaminergic, noradrenergic,
serotonergic, cholinergic and histaminergic systems have all been implicated, but the
mechanisms by which each of these systems participate to cause the various symptoms of
the disorder requires further study.
1.6 The Dopaminergic and Noradrenergic Hypothe-
ses for ADHD Aetiology
1.6.1 The Dopaminergic Hypothesis
The ability of stimulant drugs to treat symptoms of ADHD, and the DA increasing ef-
fects of these drugs have led to the logical deduction that ADHD should be the result of
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a hypofunctioning dopaminergic system. Indeed, early single photon emission computed
tomography (SPECT) imaging of [23I]atropane binding to the DAT showed a 73% higher
DAT density in the striatum of ADHD subjects (Dougherty et al., 1999). In vitro expres-
sion of the 10 repeat DAT1 gene in HEK-293 cells showed a 50% greater DAT desity than
cells transfected with the 9 repeat allele, with similar affinities to methylphenidate, and
possibly indicates increased DAT expression in 10 repeat allele carriers (VanNess et al.,
2005). This 10 repeat alle for the DAT VNTR was associated with poorer spatial attention
performance (Bellgrove et al., 2008). Taken together with the increased expression of D2
receptors (Vaughan et al., 1999) that correspond with increased D2 autoreceptor response
(Russell et al., 1995), this results in a low tonic mesolimbic dopaminergic transmission in
the ADHD subjects.
In addition to levels of DA, firing patterns of DA neurons are also highly important
in DA signalling. Low frequency tonic background firing of DA neurons is usually main-
tained, with positive reinforcements causing short-lasting phasic increases in DA release,
and error or extinction causing phasic short-lasting decreases in DA release (Hollerman
and Schultz, 1998; Schultz, 1998). Thus reduced dopamine tonic firing would require in-
creased phasic activation for adequate postsynaptic stimulation for reward to take place,
resulting in their need for more frequent and potent reinforcers in order to maintain at-
tention (Johansen et al., 2002). Likewise, low tonic DA firing would result in decreased
sensitivity to the decreased phasic DA release that would prevent the detection of an
error, resulting in decreased ability to learn from mistakes (Taylor, 1998). The resul-
tant hyperactivity was hypothesized to be due to an acquisition of various ‘intended’ and
‘unintended’ reinforcers where the extinction signals for the unintended reinforcers were
ineffective, resulting in an accumulation of responses that becomes viewed as excess motor
activity due to reinforcers that cannot be identified (Johansen et al., 2002).
However, the DAT density hypothesis for the low dopaminergic tone has been chal-
lenged by more advanced and better controlled PET studies, which have shown that DAT
density in the striatum and NAc is in fact lower in ADHD subjects than controls (Volkow
et al., 2009; Jucaite et al., 2005; Volkow et al., 2007a). Genetic linkage studies have also
associated the 9 repeat, and not the 10 repeat, VNTR of the DAT1 gene with ADHD
symptoms (Dresler et al., 2010). Decreased DAT density, as well as basal and potassium
stimulated DA release was measured in SHR synaptosomes (Simchon et al., 2010). Fur-
thermore, the lack of correlation between the effect of methylphenidate on DAT inhibition
and DA release support that the individual difference in response to methylphenidate is
more likely due to individual differences in DA release at a given level of DAT inhibition
(Ehrlich et al., 1960). DA synthesis was found to be decreased in the striatum of male
adolescents with ADHD through PET scans of L-DOPA labelling (Forssberg et al., 2006),
supported by decreased TH expression in the striatum of young SHR (Leo et al., 2003).
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Thus the decreased DAT availability could have led to the compensatory decrease in DA
levels in order to maintain homeostasis, and hyperactivity could result from a preferential
activation of the D1 receptors, since D2/D3 receptor density was found to be decreased
in the striatum, hypothalamus and NAc of adults with ADHD (Volkow et al., 2009).
Although the cause of low tonic DA availability in ADHD is under dispute, it appears
that there is agreement that ADHD is a result of a hypodopaminergic state, although
direct study of this assumption has not been possible in humans. Magnetic resonance
spectroscopy ([1H]-MRS) is a new and powerful technique that can measure absolute
concentrations of various metabolites in the human brain, however DA and its metabolites
are not currently included in the list of detectable molecules (Jansen et al., 2006). It has
been argued that the increase in extracellular DA to improve symptoms of ADHD is
not a sufficient argument for a dopaminergic deficiency hypothesis (Gonon, 2009), since
the stimulant treatments such as methylphenidate and amphetamine have been misused
frequently by healthy teenagers and young adults for their attention improving effects
(Wilens et al., 2008; McCabe et al., 2006). Of course, the dopaminergic system does not
operate in isolation, and the variety of animal manipulations have clearly shown that
various defects in any of the neurotransmission systems could result in at least one, if
not all of the behavioural impairments observed in ADHD. The dopaminergic hypothesis
emphasizes the meso-limbic and meso-cortical dopaminergic systems as the most likely
aetiological source, since pharmacological intervention at this level has been shown to be
effective. It is clear that detailed study of the manner in which the interconnected neural
systems interact in ADHD is necessary in order to understand the disorder as whole.
1.6.2 The Noradrenergic Hypothesis
Another convincing hypothesis is focused on an imbalance in the noradrenergic system.
Like the success of stimulants that have lead to the proposal of the involvement of the
dopaminergic system, noradrenergic drugs have also shown efficacy in improving the symp-
toms of attention, and support a hypernoradrenergic hypothesis. The α2A-adrenoreceptor
agonist guanfacine has been shown to improve visual object discrimination reversal per-
formance in aged rhesus monkeys (Steere and Arnsten, 1997), and improved delayed
response performance in young adult rhesus monkeys (Franowicz and Arnsten, 1998).
Treatment with the less selective α2A-adrenoreceptor agonist clonidine improved spatial
working memory in normal young rhesus monkeys (Franowicz and Arnsten, 1999). In
rats, working memory deficits induced by the anxiogenic drug, FG7142, could be reversed
with guanfacine treatment (Birnbaum et al., 2000), which also decreased hyperactivity,
impulsiveness and improved sustained attention in SHR (Sagvolden, 2006). Atomoxetine,
a selective NET inhibitor increased histamine release and improved learning deficits in the
SHR (Liu et al., 2008). The β1-adrenergic antagonist, betaxolol, was shown to improve
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working memory performance in rats and monkeys (Ramos et al., 2005).
The locus coeruleus (LC) projects widely to ipsilateral structures of the brain stem,
midbrain and all cortical areas (Jones et al., 1977; Arnsten and Goldman-Rakic, 1984).
Optimal focused attention occurs during moderate tonic NE discharge rates from the LC.
Low rates lead to low arousal and inattentiveness and high rates lead to hyperarousal and
distractibility (Foote and Aston-Jones, 1995; Usher et al., 1999). Brain areas most densely
populated with α2A-adrenoreceptors include the PFC and the LC (Aston-Jones et al.,
1999; Arnsten et al., 1996), and could explain the beneficial effects of α2A-adrenoreceptor
agonists such as guanfacine. The activation of α2A-adrenoreceptors in the LC by agonists
such as guanfacine should cause a net decrease in its noradrenergic response to excita-
tory stimuli (Ivanov and Aston-Jones, 1995), and thus modulate LC discharge rates to
improve sustained attention of those with ADHD. The noradrenergic hypothesis supports
that a hypernoradrenergic system may possibly cause ADHD symptoms (Zametkin and
Rapoport, 1987; Biederman and Spencer, 1999).
In vitro superfusion studies in the SHR have shown increased noradrenergic activity
and decreased dopaminergic activity (Russell et al., 2000; Russell, 2002). [3H]dopamine
release from the nucleus accumbens in SHR was inhibited through the action of α2A-
adrenoreceptors (de Villiers et al., 1995). In fact, the beneficial pre frontal cortical cogni-
tive effects of methylphenidate have been shown to be mediated through α2A-adrenoreceptor
and dopamine D1 receptor actions in rats (Arnsten and Dudley, 2005).
Genetic studies have also reported associations of ADHD with adrenergic genes (Com-
ings et al., 2000), particularly the NET1 (Bobb et al., 2005a; Kim et al., 2008). Recent
genome-wide association scans have additionally implicated the α1A- and β2-adrenoreceptors
(Lasky-Su et al., 2008), while the α2A-adrenoreceptor gene has been linked to specifically
to the ADHD-I subtype (da Silva et al., 2008; Schmitz et al., 2006), providing further
support for the noradrenergic basis for ADHD.
A catecholaminergic imbalance in ADHD is undisputed, although further studies are
required to determine the relative interactions and contributions of each system for a more
comprehensive understanding of ADHD aetiology.
1.7 in vivo Chronoamperometry
Few in vivo studies of the dopaminergic system in the SHR have been performed, all of
which made use of microdialysis. The microdialysis technique is able to measure basal
metabolite and neurotransmitter concentrations accurately, however the temporal resolu-
tion of microdialysis data is poor (tens of minutes). In contrast, in vivo chronoamperome-
try offers the ability to measure changes in dopaminergic concentrations within millisecond
time scales, and micrometer spatial resolutions (Kawagoe et al., 1993). Thus, this type of
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electrochemical recording can provide dynamic, real-time information of neurotransmit-
ter release and clearance kinetics in discretely localized areas in animals (Gerhardt et al.,
1999). When this recording technique is coupled with KCl stimulation and exogenous
application of DA (by pressure ejection), it becomes possible to functionally map areas of
the rat ST and NAc, which is difficult to achieve using other methods (Kawagoe et al.,
1993). In vivo chronoamperometry has been used to study DAT activity in the DAT-KO
mice (Gainetdinov et al., 1999; Gainetdinov, 2008), but none have yet been published for
the SHR.
The use of in vivo voltammetric recordings for the analysis of neurotransmitters and
neurochemicals in the central nervous system was pioneered by Ralph Adams in the early
1970s (Wightman et al., 1976). The concept of the technique is elegant in its simplicity.
When the electropotential of an electrode is made sufficiently positive, it acts as an oxidant
to molecules near its surface; electrons transfered to this surface by the molecules can be
measured as current, that is directly proportional to the number of molecules oxidized,
according to Faraday’s Law (Adams and Marsden, 1982). Thus the concentration of the
molecules at the electrode tip can be accurately calculated.
Typically, sensing or working electrodes are made with substances with low residual
current such as carbon-pastes or graphite-epoxy resin, so that the current measured is
a direct result of the molecules in contact with it, and not from the sensor material.
Although highly sensitive, the selectivity of electrodes for specific substances of interest
has been a major challenge in the field of electrochemistry. For example, DA, NE, 5-HT
and ascorbate all oxidize at an applied potential of +0.55V, and the interpretation of the
current measured from the cumulative oxidation of these substances is thus limited, since
relative contributions of metabolites cannot be calculated. Considering the high amounts
of ascorbate present in the brain, and its apparent differential distribution among the
regions (Ewing et al., 1982; Stamford et al., 1984), its contribution to the measured signal
was a large confounding factor. Various alterations of the electrode surface to improve
its selectivity for specific substances have since been developed, and current technology
allows for accurate detection of various molecules such as nitric oxide (NO) (Barbosa
et al., 2008) and l -lactate (Burmeister et al., 2005), as well as neurochemicals such as
glutamate, acetylcholine, NE, 5-HT and dopamine (Bruno et al., 2006; Day et al., 2006;
David et al., 1998).
Particularly relevant for this project, the coating of the carbon electrode tip with
Nafion was found, by Greg Gerhardt, to dramatically improve the selectivity of graphite
electrodes for the measurement of cationic neurotransmitters. Nafion is a perfluorosul-
fonated polymer that renders the electrode practically impermeable to ascorbic acid and
other anionic biogenic amine metabolites (Gerhardt et al., 1984). However, the Nafion
treated electrodes would sense NE, 5-HT as well as DA; greater selectivity for DA can be
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achieved by placing the electrode in an environment, such as the rat striatum, where DA
concentrations are high, and other neurotransmitter concentrations are low. In this way,
the chemical exclusion of interferents like ascorbate by Nafion, and the locational exclu-
sion of other transmitters by targeting DA rich areas in the brain, affords measurements
of high accuracy for DA specifically (Adams and Marsden, 1982; David et al., 1998).
In vivo chronoamperometry is thus a powerful technique for measuring the dopamin-
ergic response to stimulations in real time, and ideal for the study of dopaminergic neu-
rotransmission in vivo, in SHR. The generous donation of the equipment required for this
technique from Greg Gerhardt allowed for its set-up in this laboratory.
The SHR is the most widely validated animal model for ADHD (Russell, 2007), how-
ever data regarding its dopaminergic function are currently contradictory and require
further study. The in vivo chronoamperometry technique allows for the measurement
of dopaminergic concentrations at high temporal and spatial resolutions, and has never
yet been studied in the SHR at the time of this dissertation, and has never been set-up
in this laboratory. Methylphenidate and guanfacine have exhibited the ability to im-
prove cognitive function and reduce hyperactivity in children with ADHD (Taylor et al.,
2004; Minzenberg and Carter, 2008; Biederman et al., 2008b). Thus, the present project
elected to set-up the in vivo chronoamperometry technique in this laboratory and study
potassium-stimulated release and uptake of exogenously applied DA in the striatum of
the SHR. Additionally, the behavioural effects of methylphenidate and guanfacine on
voluntary running activity and in the open field test were measured.
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1.8 Aims
1. Verify strain purity of SHR and WKY stock at UCT.
2. Set-up in vivo chronoamperometry technique.
3. Record dopamine release and uptake parameters in anaesthetised SHR, WKY and
SD rat strains, using in vivo chronoamperometry.
4. Characterise behavioural effects of methylphenidate at various doses on voluntary
use of Running Wheels.
5. Characterise behavioural effects of guanfacine at a single dose in the Open Field
and in Running Wheels.
28
2 DNA screening at 3 SNP loci
2.1 Introduction
The SHR, WKY and SD rats are albino strains which appear identical. Cross-breeding
and strain contamination was a likely possibility. In December of 2008, samples from the
University of Cape Town (UCT) stock of SHR and WKY were sent to Syracuse, New
York for genome wide comparisons of 10 000 SNPs with other SHR and WKY stock from
around the world. It was found that 1 of our WKY samples was a clear heterozygote
between the SHR and WKY strains. Since the studies of the SHR model of ADHD is
largely based on comparisons against the WKY strain, genetic screening of the SHR and
WKY stock at UCT was required to ensure that the strains were not cross-contaminated
prior to further breeding in the Animal Unit.
Dr Frank Middleton, Director, Microarray Core Facility and Center for Neuropsychi-
atric Genetics, SUNY Upstate Medical University, New York, USA generously provided
3 SNPs that would distinguish between the SHR and WKY strains, and identify mixed
strains. These included ‘D1RAT47’ on chromosome 1, ‘D2RAT62’ on chromosome 2 and
‘D3RAT24’ on chromosome 3.
A search on the Rat Genome Database indicated that the expected SNP band sizes for
the SHR/NCrl, WKY/NCrl (SHR and WKY from Charles River, USA) and WKY/NHsd
(WKY from Harlan, UK) were identical and not polymorphic between the strains; 162
bp for D1RAT47, 166 bp for D2RAT62 and 151 bp for D3RAT24. Strain variations
of expected product sizes of these SNPs occur for SHR/OlaHsd rats (SHR from Harlan
Spague Dawley Inc, Indianapolis), which were 164, 191 and 151 bp, and for WKY/OlaHsd
(WKY from Harlan Spague Dawley Inc, Indianapolis) which were 154, 177 and 144 bp for
the D1RAT47, D2RAT62 and D3RAT24 SNPs respectively (http://rgd.mcw.edu, accessed
28-08-2010).
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2.2 Methods
2.2.1 Tissue Collection
Animals were born in the main UCT Animal Unit where food and water was available
ad libitum, temperature was controlled between 22 ∼ 24 ◦C and 12 hr light/dark cycle
(06:00 lights on) was maintained. Tail snips (approx 3 mm) and ear punch material were
collected from a total of 45 SHR and 52 WKY pups between P 21 and P 30 by an ani-
mal technician. Rats born from ‘SHR’ dams were labelled ‘1’ in their first digit of their
identification number, and ‘WKY’ were labelled ‘2’. Subsequent identification numbers
were given in the order of collection. Tissue samples were stored at -20 ◦C until DNA
extraction. This procedure was approved by the UCT Faculty of Health Science Animal
Research Ethics Committee. Project number: 009/025.
2.2.2 DNA Extraction
Collected tissue samples were incubated in 450 µl Tail Buffer (1% SDS, 0.1 M NaCl,
0.1 M EDTA, 0.05 M Tris pH8) and 15 µl Proteinase K (20 mg/ml) at 50 ◦C between
1 ∼ 4 days (until the tissue was dissolved). Potassium acetate (200 µl of 5 M solu-
tion) was then added to each sample, shaken vigorously and left to stand for 2 min.
Samples were centrifuged at 16 000 g for 3 min to exclude proteins. Each supernatant
was placed in a new vial, to which 700 ∼ 800 µl of isopropanol (100%) was added.
The mixture was shaken, left to stand for 2 min, and centrifuged again at 16 000 g
for 3 min to pellet the DNA out of solution. The supernatants were discarded and
each pellet was washed with 600 µl ethanol (70%) and centrifuged for the last time
at 16 000 g for 3 min. The supernatants were discarded and pellets left to air dry
for 20 ∼ 30 mins with the vial lids open. Pellets were resuspended in 50 µl of Tris
EDTA (TE) Buffer (10 mM Tris-HCL pH 7.5, 1 mM EDTA) and stored at 4 ◦C until
determination of DNA concentration and purity with a Nanodrop1000 spectrophotome-
ter. DNA templates were diluted to 200ng/µl as required for polymerase chain reaction
(PCR).
2.2.3 Polymerase Chain Reaction
Primer pairs for SNPs D1RAT47, D2RAT62 and D3RAT24 (Sequnces in Appendix A.1)
were manufactured by Whitehead Scientific. Pellets were reconstituted in TE buffer in
100 µM stock solutions and diluted to 10 µM working solutions.
For each 25 µl reaction, a primer pair (D1/D2/D3; ∼10 ng F and R), template DNA
(∼200 ng), 2× GoTaq R© Green Master Mix (Promega Corporation) and dH2O made up
the total, were combined in a 200 µl PCR tube. The thermalcycler was programmed with
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an initial 95 ◦C for 5 mins for activation of GoTaq R©. Amplification occured through 40
cycles of the following: 95 ◦C - 30 s; 56 ◦C - 30 s; 72 ◦C - 40 s. Finally, the temperature
was held at 72 ◦C for 7 mins for elongation of products. Each sample was run at least
twice, on different days to ensure accuracy.
2.2.4 Visualization
Agarose was dissolved in TBE buffer (4%), ethidium bromide (EtBr) (1%) was added
immediately prior to casting. Once set, gels were placed in horizontal electrophoresis
tanks filled with TBE buffer. Each PCR sample was loaded and run at 60 V for 180
mins. GeneRuler Ultra Low Range DNA Ladder (Fermentas) was used in at least one
but usually two lanes of each gel. Bands were detected via UV light and images were
captured with UVCentral Software.
Band sizes were calculated by the generation of standard curves from distances moved
by each band of the ladder vs log of each band size for each gel. Standard curves were
fitted with Excel 2007 (Microsoft). The resultant band sizes of D1RAT47, D2RAT62 and
D3RAT24 SNPs were calculated from the distance travelled by the band in relation to
the standard curve of the gel. Band sizes of replicate gels were averaged to produce one
size per band.
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2.3 Results
Determination of DNA concentration using a spectrophotometer showed a very high aver-
age yield of 1090.7 ng/µl, with a standard deviation of ±420.6 ng/µl. The 260/280 ratios
were 1.98 ± 0.05, and 260/230 ratios were 1.85 ± 0.19. Of the 97 collected tissue samples,
9 samples did not contain sufficient tissue for successful extraction of DNA templates and
were discarded. Discarded samples were random and each had corresponding littermates
that produced high yields of DNA templates.
A typical 4% agarose gel following the PCR amplification presented clear amplified bands
with expected primer dimers around the 50 bp range (Fig. 2.1).
Figure 2.1 – An example gel showing DNA ladder on the far left; SHR is indicated by ‘1’
in the first digit, WKY indicated by ‘2’ in the first digit; Number following the first digit
labels the individual rat; D1/D2/D3 indicate the targeted SNP; Bands around 50 bp were
primer dimers; Double band was detected in 201D1
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An example of a standard curve generated from a gel showed the expected linear
relationship between the log of the MW of the ladder vs the distance migrated by the
band on the gel (Fig. 2.2).
Figure 2.2 – Example of a standard curve generated from the ladder rung of Gel 17 with
fitted equation
The median of band sizes of our WKY D1RAT47 D2Rat62 and D3RAT24 band sizes
were 5, 8 and 2 bp larger than the WKY/OlaHsd respectively. SNP band size differences
between strains showed that the medians of the SHR were 12, 16 and 39 bp larger than the
WKY bands for the D1RAT47, D2RAT62 and D3RAT24 SNPs respectively (Table. 2.1).
Thus although the D1RAT47 and D2RAT62 SNPs showed the expected approximate 10
bp difference between our strains, the D3RAT24 SNP in the SHR was almost 4 times
longer than the expected 10 bp difference suggested by Dr Middleton.
Table 2.1 – Difference in median and mean SNP sizes (bp) between SHR and WKY samples
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An acceptable range of band sizes for each SNP of each strain was calculated by the
median± the standard deviation (Fig. 2.2). The rats of all samples that produced bands
that did not fall within the ranges were excluded as possible future breeders. In total, 8
SHR and 12 WKY were selected for breeding.
Table 2.2 – Median, mean and standard deviations of SNP sizes (bp) of SHR and WKY
samples, with comparison to the expected SNP sizes of rats from Charles River, USA
(/NCrl), Harlan, UK (/NHsd), and Harlan Sprague Dawley Inc, Indianapolis (/OlaHsd)
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Table 2.3 – SNP sizes from all SHR and WKY samples. Highlighted blocks indicate band
sizes that did not fall within the acceptable ranges. Rats that were selected for future
breeding are marked with (o)
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Table 2.4 – Continuation of previous table. SNP sizes from all SHR and WKY samples.
Highlighted blocks indicate band sizes that did not fall within the acceptable ranges Rats
that were selected for future breeding are marked with (o)
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A subsequent RatGenome Database search revealed the strain variations that could
be expected from the 3 SNPs that were analysed in the present study (Table. 2.5).
Table 2.5 – Strain variations of the 3 SNPs used in this study according to the Rat Genome
Database
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Table 2.6 – Continued. Strain variations of the 3 SNPs used in this study according to the
Rat Genome Database
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2.4 Discussion
The yields achieved from the DNA extractions were high. Each PCR reaction required
only only 200 ng/µl, and at least 500 µl of high concentration genomic DNA template was
extracted from the samples that had sufficient tissue. Those samples that did not contain
sufficient tissue were discarded, however each discarded sample had other littermates that
should have had similar genetic profiles. Residual ethanol content was possibly high as
reflected by the 260/230 ratios, and 260/280 ratios suggested that samples were devoid
of protein contamination, but may contain some level of RNA, however neither ethanol
or RNA interfered with the PCR amplifications, since the high yield of template DNA
required very low volumes of the extracted templates to be used (typically 1 µl), and
thus the level of ethanol and RNA in the reaction samples would be negligible. Since the
expected difference in SNP band sizes between the strains were so small (∼10 bp), a high
percentage agarose gel (4%) was required in order to differentiate the bands. Gels were
run at very low voltage over a long period of time in order to minimize the amount of
heat and shearing of the bands through the agarose medium.
The SHR and WKY of this study were reportedly purchased from Charles River
Laboratories, USA (Personal communication with UCT Faculty of Health Sciences Animal
Unit manager), However the calculated medians of the SNPs for each strain showed smaller
differences with the expected SNP sizes of SHR and WKY from Harlan, Indianapolis, and
much larger differences when compared with the expected band sized of rats from Charles
River, USA or Harlan, UK. The present results suggest that the rats in the Animal Unit
were more likely to have been purchased from Indianapolis, and not Charles River. The
reported expected band sizes from the Rat Genome Database are exact sequenced sizes,
and the slight differences in band sizes between the calculated band sizes of our SHR
and WKY compared to the exact band sizes of the SHR/OlaHsd and WKY/OlaHsd was
not surprising. However, this assumes that the UCT rats were in fact purchased from
Indianapolis.
In the present study, the SNP band sizes were calculated according to the distance
migrated compared to ladder bands of known sizes. The sizes of expected bands were
unknown in this study because should both strains have originated from Charles River
USA, there would have been no expected variability in these 3 SNP loci according to
the Rat Genome Database, however polymorphisms were found at the loci. Thus the
medians of all of the generated bands for each SNP for each strain were taken to be the
‘correct’ size to expect for our SHR and WKY, and an ‘acceptable range’ was calculated
from the median±standard deviation to account for gel, measurement and standard curve
variabilities.
There is a possibility that rats that were of pure strain were excluded from breeding
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as a result of this selection method, since there were rats that did not show double bands,
but were exluded due to band sizes that did not fall within the calculated acceptable size
range. However, calculated band sizes could be variable because of different brands of
agarose, electrophoresis tanks and powerpacks used on the various experimental days, in
different laboratories. These difference could have changed the rate at which the bands
were pushed through the gel and changed the slope of the standard curve and thus the
calculated band size, and without known pure strain SNP samples for each strain to run
on the gels as controls, this type of variation could not be accounted for. However, it
was decided that it would be more prudent to maintain a more stringent selection pro-
cess, since the number of generations that had passed since the possible cross breeding
was unknown, and whether it was possible that with chromosomal crossing over during
fertilizations, some SHR could have bred to have homozygous SNP alleles that were char-
acteristic of WKY size, and vice versa.
The bands that were larger than the median+standard deviation were suspected to
have been due to the binding of primers onto the amplified SNPs, since some samples were
kept at ◦C overnight prior to gel electrophoresis the subsequent day. However, these bands
occured repeatedly in the D2RAT62 SNP. When PCRs were repeated without overnight
incubation of products, the same results were observed. Non-specific amplification could
also explain bands that were too small or too large. This appeared likely, since it occured
mainly for the D2RAT62 and D3RAT24 SNPs. Perhaps the Taq or primers were not
sufficiently specific, and caused an amplification of other bands around 250 bp in the
D2RAT62 SNP.
Post selection, it was observed that the median size for the D3RAT24 SNP in the
SHR was 34 bp larger than the expected size at this locus for SHR of any origin. Bands
around the expected 151 bp occured only 7 times and were always accompanied by the
larger bands that were of similar size to the calculated median. This observation suggests
that all of the SHR that produced an unexpected band of around 185 bp were selected
for breeding, while rats that produced the expected SNP sizes of around 151 bp were not
selected for further breeding, although double bands occurred for every ∼151 bp band
that appeared, which would have excluded the same rats from selection. However, the
origin of the 185 bp bands that were so numerous that it was selected as the ‘correct’ band
is unknown. Possible candidates of the origin of this band size at this locus according
to the Rat Genome Database are the Stroke Prone SHR of the Riv substrain, SD of the
Rij substrain or diabetes prone rats BBDP/Rhw and BBDR/Rhw where the D3RAT24
expected SNP size is 182 bp. The diabetes prone rats are less likely, since their darker,
piebold/grey fur and much larger body mass render them easily distinguishable from
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the SHR, however the SHRSP and SDs appear identical to our SHR and cross breeding
between these strains could have been possible. In fact, the median band sizes of D1RAT47
and D3RAT24 our SHR were more similar to the SD/Rij than to SHR/OlaHsd, while the
D2RAT62 SNP was more similar to the SHR/OlaHsd. These results suggest that although
‘pure’ SHR were selected on the basis that they were homozygous for our calculated
expected band sizes, there were no SHR that were homozygous for all 3 of the SNPs of
the size expected from a pure SHR/OlaHsd strain, and that all of the sampled SHR were
possible crossed with SD/Rij. This interpretation would suggest that a separate strain
crossing had occured since the initial 10 000 SNP screening in Syracuse, New York, which
had revealed only a direct SHR and WKY cross, and no involvement of the SD strain.
Only 3 SNP loci were examined per rat in this screening, and it was possible that
during chromosomal crossing over and breeding over an unknown number of generations,
mixed strains could become homozygous for some of these alleles but not others. Thus
some loci could produce single bands, however they could have been single bands of a
different rat strain. If this were the case, the optimal solution would be to purchase new
stock from Charles River or Indianapolis, since this laboratory is not equipped for whole
genome screening.
Recent advances in genetic technologies and the focus that the SHR receives due to
its validated importance for the study of hypertension has led to full genome sequencing
of the SHR/Ola (NIH decendants), as well of the progenitor normotensive strains, now
available on SHRBase (http://shr.csc.mrc.ac.uk/index.cgi) (Pravenec and Kurtz, 2010).
Embryonic stem cells have also been developed from rat blastocysts in the rat (Buehr
et al., 2008), and the phenomenal technology of targeted gene KO with the use of zinc-
finger nucleases (ZFNs) has been shown to reliably knock out genes of choice with between
25% to 100 % efficiency, that are also faithfully transmitted through the germline, via a
single microinjection (Geurts et al., 2009). The technologies that were available for the
manupulations of the mouse genome since 1981 (Buehr et al., 2008) are finally available
for the rat. These powerful new technologies will provide unprecedented opportunities to
identify gene functions of each of the variants systematically (Pravenec and Kurtz, 2010)
and will not only advance the study of SHR for hypertension, but also allow the study of
direct contributions of each implicated gene in ADHD on behavioural phenotypes. The
variants between the impulsive and non-impulsive subpopulations of the SHR (Adriani
et al., 2003) could lead to the identification of the genetic basis of impulsiveness (at least
in the SHR, but could have wider implications). Finding overlapping variants between
the SHR/NCrl, WKY/HA and WKY/HT would have the potential to identify the genetic
basis of hyperactivty. Further, heterogeneity of the SHR can be even more stringently
controlled, and aid conclusions that can be drawn from comparative neurochemical and
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behavioural studies. With the assistance of genetic technologies, further research on the
SHR as an animal model for ADHD is highly promising and exciting.
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3 In vivo Chronoamperometry
3.1 Introduction
As introduced in section 1.7, the measurement of accurate dopamine concentrations in
the striatum of the SHR in real time and high spatial resolution is possible with the
use of in vivo chronoamperometry and Nafion coated carbon fibre electrodes (Day et al.,
2006; Bruno et al., 2006). Much research has been performed in vivo in adult Fischer-
344 (Friedemann and Gerhardt, 1992; Diao et al., 1997; Cass and Gerhardt, 1995) and
SD (Gerhardt et al., 1987) rats, as well as rhesus monkeys (Cass et al., 1995; Gerhardt
et al., 1996) with this technique, and the parameters for the measurement of dopamine
in vivo have been thoroughly optimized, especially in anaesthetized animals. Studies
utilizing the carbon fibre electrode in freely moving rats have also been performed (Sabeti
et al., 2002), however, since the technique had never been set-up in this laboratory, it was
not recommended to attempt to record from freely moving SHR at this stage (personal
communication with Gregory Gerhardt).
The present study utilized well established parameters that could detect dopamine
most reliably in the rat striatum, as published by the Gerhardt laboratory (Friedemann
and Gerhardt, 1992; Diao et al., 1997; Cass and Gerhardt, 1995; Gerhardt et al., 1987) in
order to assess the success of the set-up and acquire comparable data. An applied potential
of -0.55 V between the working electrode and the reference electrode was used to cause
the oxidation of a narrow range of molecules, of which NE, 5-HT and DA were most
relevant. Measurements were taken from the SHR ST and NAc firstly due to its regional
relevance of the ADHD hypotheses, and additionally to minimize the contributions of NE
and 5-HT from recordings. Animals were deeply anaesthetized with urethane as it was
shown to minimally interfere with DA neurotransmission (Sabeti et al., 2003).
Potassium stimulated release of endogenous DA aimed to measure and compare pos-
sible differences in the amplitudes of DA released between the SHR, WKY and SD rat
strains, thus the volume of KCl applied was controlled. DA clearance rates were measured
by the application of exogenous DA of varying volumes such that the amplitudes attained
were controlled, and served as an indication of DAT activity. Each application of either
potassium or exogenous DA increased the regional DA concentration until the peak am-
plitude was reached. The subsequent decline of the DA concentrations was measured as
the clearance rate. The T80 and T50 parameters were the time (s) for the concentration of
DA to decrease to 80% or 50% of the peak amplitude respectively, while Tc, was the time
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of clearance between 60% to 20% of the peak amplitude.
Conclusions that can be drawn from the results recorded from anaesthetized animals
are limited and cannot be extrapolated directly to freely moving animals, or humans.
However information obtained in this manner serves to characterise the neurochemistry
of SHR under these conditions, which would be comparable with other studies (Sabeti
et al., 2003; Gerhardt and Burmeister, 2000).
3.2 Methods
3.2.1 Animals
Animals were tranferred to the satellite Animal Unit at P 21. Food and water was available
ad libitum, temperature was controlled between 22 ∼ 24 ◦C and a 12 hr light/dark cycle
(06:00 lights on) was maintained. Rats were kept with littermates, between 2 ∼ 5 per
cage until surgery. Rats from 75 g ∼ 160 g were used between P 32 ∼ P 37. Including
initial tests that do not contribute to the analyzed data, a total of 20 SHR, 15 WKY
and 13 SD were utilized in this study. In the portion of the experiments where KCl was
used to stimulate endogenous DA release, the results from 8 SHR, 8 WKY and 7 SD
were used; in the portion of the experiment where exogenous DA was applied, the results
from 9 SHR, 9 WKY and 5 SD were used, however some rats were involved in both the
KCl and DA experiments. 4 SHR and 2 WKY were used to test the accuracy of the
stereotaxic apparatus and the histology technique. This experiment was approved by the
UCT Animal Research Ethics Committee. Project numbers: 009/005 and 009/065.
3.2.2 Equipment Set-Up
Immediately after the arrival of the core components of the FAST equipment in March
2009, our laboratory began the attempt to set it up. Although there was much support
from the Lexington labs through Skype and email contacts, and previously published
papers of this technique were consulted thoroughly, many practical details of the set-up
remained elusive. Fortunately, I was able to visit the Gerhardt laboratory for two weeks
in July 2009 where I obtained all of the critical details required to set-up the equipment
and received practical training to use this technique effectively.
3.2.2.1 Equipment Components
The hardware components include the Fast Analytical Sensing Technology (FAST) mkI
Control Box (black), a picospritzer (white) and a headstage (Fig. 3.1), which communicate
with the FAST v2.3 computer program (Fig. 3.2). In addition, a pulled and bumped glass
micropipette, a carbon fibre working electrode and silver chloride reference electrode were
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required for each experiment. The preparation methods for each of these are detailed
below. Briefly, the sensing tip of the electrodes were inserted into defined brain areas,
while the opposite end was connected to the headstage, which connected to the FAST
control box, and finally the FAST program. The FAST v2.3 program, along with the
appropriate drivers were installed on a dedicated computer, with the anti-virus programs
removed. The program was set to detect signals from a ×50 headstage (20 pA/mV) and
the FAST mkI Control Box. Gain settings for Channel 1 on the control box were set at
‘2×’ and corresponded to the settings on the software.
Settings were verified in the Amperometry environment in the program where the
Applied Potential was set to -0.5V to produce a +0.55V against the Ag/AgCl reference
electrode. The current measured when a 10 MΩ resistor connected between the ‘Ref’ and
‘E1’ jacks was confirmed to be 5 nA.
Figure 3.1 – Headstage connects electrodes to FAST Control Box. A 10 MΩ resistor
connecting the ‘Ref’ and ‘E1’ jacks should produce 5 nA reading in the amperometry envi-
ronment (Applied Potential = - 0.5V) once the correct settings had been selected.
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Figure 3.2 – Photograph of FAST set-up in our laboratory. FAST Control Box connects
the Headstage (at the Calibration Station in this photograph) to the computer program.
Picospritzer connects to the top of a glass micropipette in the Surgical Station via a plastic
tube.
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3.2.2.2 Trouble-shooting of Electrical Noise
Electrical noise is a notorious problem in all electrophysiological studies, and this study
was no exception. The laboratory was fortunately previously re-wired so that certain
plugs were earthed to a single location in the building. All equipment involved in the
FAST recordings (FAST Control Box, picospritzer and computer) were attached to this
lead only. A Faraday cage did not decrease the amount of noise detected in the system,
and it was suggested by the Lexington team to exclude the cage. Additionally, every piece
of electrical equipment in the laboratory was checked for whether it influenced the shape
of the oscilloscope in the FAST program (Fig. 3.3). Eventually it was determined that
virtually no other equipment, especially the drill and lamps, could be plugged in to any
socket in the laboratory during chronoamperometry recordings. The standard magnetic
stirrer was exchanged for a battery operated stirrer to prevent electrical noise during
calibration.
(a) Oscilloscope with noise (b) Oscilloscope without noise
Figure 3.3 – a) Oscilloscope detected much electrical noise when the drill and lamps were
plugged in. b) Noise was eliminated when other equipment in the laboratory were not
plugged in.
3.2.2.3 Stereotaxic Station
A stereotaxic frame was dedicated to the set-up. This frame required the addition of a
vertical microdrive. Adjustments were also made so that all planes moved correctly, i.e.
the microdrive moved vertically, perpendicular to the floor, and not at any angle, and
that the AP and ML planes moved perpendicularly to each other, parallell to the floor.
A dissection microscope was required for the surgery, and a reticule for the microscope
was required for measuring the volume ejected from the glass micropipette. A dissection
microscope that was able to receive a reticule in its eyepiece was eventually found, and
the the reticule successfully installed.
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A heating pad capable of controlling the temperature at 37 ◦C was required to maintain
rat body temperature under anaesthesia. Several of these were tested and the one which
caused the least electrical noise in the system was selected for use.
3.2.2.4 Micropipette Puller Adjustments
The were several micropipette pullers in the laboratory, however none were successful at
producing the required uniform taper that is 1 cm in length at any combination of heat
vs solonoid settings. It was finally concluded that the length of the coil on our puller was
too short to produce the parameters that we require. A new, longer coil was fashioned
and fitted, and we were finally able to produce micropipettes of ideal taper and length as
stipulated by the Gerhardt laboratory.
The pulled micropipettes were successfully bumped to inner diameters of ∼10 µm and
stored in dust-free containers until they were ‘waxed’ to working electrodes.
3.2.2.5 Calibration of Volume of Liquid in the Glass Micropipettes
Minute volumes of approximately 50 ∼ 250 nl of KCl and DA needed to be delivered from
the pulled and bumped glass micropipettes, through pressure ejection via the picospritzer.
This volume could only be measured via the distance of liquid displaced along the tube
of the micropipette, as viewed through the dissection microscope with fitted reticule.
Although it was previously published by the Gerhardt laboratory, we performed our
own measurements to determine the amount of liquid in 1 cm of the tube. The masses
of 5 empty micropipettes were taken. Micropipettes were each filled with distilled H2O,
the lengths of the fluid in the tubes were measured with vernier calipers, and the masses
of each tube including the water were recorded. Some fluid was then expelled from each
tube, the new lengths of the fluid were measured, along with the new masses. Since 1 ml
of dH2O is 1 g, we were able to determine that 1 cm of these micropipettes held 250±6
nl.
3.2.3 Preparation of the Working Electrode
3.2.3.1 Description of Working Electrode
Working electrodes were purchased from CenMet (Quanteon Ltd.). The tip of a carbon
fiber working electrode consisted of a carbon fibre (30 µm in diameter) supported by a
micro-glass pipette (∼30 µm inner diameter) such that a length of 150∼200 µm protruded
from the glass support. The carbon fibre was connected to a copper wire via compacted
Graphpoxy in the funnel portion of the micro-glass pipette support (Fig. 3.4). Upon
arrival, working electrodes were stored at -20 ◦C until Nafion coating.
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Figure 3.4 – Diagram of a carbon fibre working electrode.
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3.2.3.2 Nafion Coating
Nafion (Sigma-Aldrich) was aliquoted into 2 ml, light-proofed, air-tight glass vials upon
opening of the original bottle. Each aliquoted vial was used for a maximum of 2 weeks
once it had been opened.
Working electrodes were removed from the -20 ◦C freezer. The tip of each electrode
was rinsed briefly in distilled H2O, and immediately baked at 200
◦C for 5 mins to dry. The
electrodes were carefully removed from the oven and the tips were dipped into the Nafion
vial and swirled 3 times around the inner circumference of the vial, without touching the
glass. The dipped electrodes were baked at 200 ◦C for another 5 mins to bind the Nafion
coating. All electrodes were used within 2 weeks of Nafion coating.
Each coated working electrode was ‘waxed’ together with a pulled and bumped glass
micropipette. Literally, the electrode and pipette were manipulated under a reticuled
microscope until their tips were flush, parallell, in the same plane, with the inner diameters
180 ∼ 220 µm apart, and finally held together in this position by sticky wax (Fig. 3.5).
The end of the copper wire was stripped and soldered to an amphenol that would
connect the working electrode to the the headstage.
Figure 3.5 – Diagram of working electrode waxed to pulled and bumped glass micropipette.
Micropipette inner diameter was bumped to ∼10 µm. Working electrode was flush, parallel
and in the same plane as micropipette, and between 180 ∼ 220 µm apart, then held together
by sticky wax. Amphenol was soldered to stripped end of working electrode.
50
Methods Chapter 3. In vivo Chronoamperometry
3.2.4 Construction of the Reference Electrode
Each reference electrode was constructed with approximately 10 cm of teflon coated silver
wire (AM-Systems). Both ends of the wire were stripped (approx 7 mm) and one end was
be soldered to an amphenol. The other end of the wire was chlorided at approximately
10 V with a DC adapter in a bath containing 1 M HCl saturated with NaCl.
3.2.5 Calibration
Each electrode was calibrated immediately prior to use in the rat brain. An RE5b glass
reference electrode (BASi) was used for the calibrations as it is more sensitive and stable
than those constructed for in vivo experiments. It cannot be used for in vivo work as it
is too large and cannot be manipulated to fit in the rat skull.
In the calibration window of the FAST program set for square wave chronoampero-
metric recording, The applied voltage was set at -0.55 V, and resting voltage at 0 V. The
pulse period was set to 0.2 s, which was the total duration of the voltage pulse. The
sweep time was set to 1 s, which was the interval between the start of voltage pulses. The
amount of current (nA) in a 40 ml of gently stirred phosphate buffered saline (PBS) lite
(0.01 M NaH2PO4; 0.04 M Na2HPO4; 0.1 M NaCl) was measured and marked as ‘base-
line’. Then, 500 µl of freshly made ascorbic acid (20 mM) was added to the 40 ml beaker,
and the current for the final concentration of 250 µM of ascorbic acid was measured and
marked as ‘interferent’. 40 µl of DA (2 mM) was added to the beaker and the current for
the final concentration of DA (2 µM) was marked as ‘analyte 1’, ‘analyte 2’ was measured
with a further addition of 40 µl that increased the total concentraiton of DA to 4 µM, and
a final ‘analyte 3’ was measured in the same manner. These measurements allowed for
the calculation of the Limit of Detection (LOD), electrode selectivity of DA over ascorbic
acid, linearity of the relationship between current and DA concentration (R2) and slope.
Essentially, the current sensed by the electrode was equated to the known concentrations
of DA in the beaker to enable the calculation of DA concentrations when in vivo. Pa-
rameters for useable electrode included an LOD of <0.1 µM, selectivity in the oxidative
channel >100 and R2 >0.98.
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Figure 3.6 – Photograph of calibration set-up. Glass reference electrode and waxed working
electrode are connected to the headstage at the non-sensing end. The sensing ends of the
electrodes are in the 40 ml glass beaker inititally containing PBS lite. Magnetic stirrer was
battery operated to prevent electrical noise
3.2.6 Surgery
Each rat was weighed and anaesthetized with 25% urethane (i.p. 1.25 g/kg with boost-
ers to 2.5 g/kg) given over approximately 2 hrs. The rat was determined to be stably
anaesthetized when it no longer exhibited any pain (toe pinch) or eye blink reflexes. Sub-
sequently, the hair on the head was removed, the rat was placed on the heating pad and
secured with the ear and incisor bars in the stereotaxic frame. The skin of the head was
reflected and the part of the skull over the striatum was removed bilaterally (approx AP
-1 ∼ +2 mm; ML ±1.5 ∼ ±3 mm) (Paxinos and Watson, 2005). A small hole was drilled
in the posterior, lateral part of the skull for the placement of the reference electrode
(Fig. 3.7). A saline soaked cotton ball was placed over the left side of the brain to prevent
dessication while experiments were conducted on the right side of the brain. The meninges
over the right side of the brain were removed and the area cleared of blood. The glass
micropipette of the working electrode construction was filled with KCl (120 mM) and the
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construct was lowered to DV 3.0 of the right side of the brain at co-ordinates AP +1;
ML -2.5 mm. The working electrode was always oriented posterior to the micropipette.
The Ag/AgCl reference electrode was hooked into the hole in the posterior of the skull,
between the skull and the meninges. Saline soaked cottons balls were placed around the
working electrode to prevent dessication of the brain. The picospritzer was connected to
the end of the glass micropipette and the drill and lights were unplugged. The electrodes
and rat were allowed to equillibrate for 1 hr to reach baseline. A setting of 20 psi and
Figure 3.7 – Diagram of stereotaxic surgeries with working and reference electrode place-
ments.
500 ms on the picospritzer was used to check that the micropipette was not obstructed.
The duration and pressure of the ejection would be adjusted until the volume of KCl
ejected was between 100 ∼ 250 nl. After ejection of the correct volume at DV 3.0 mm,
the stimulated peak was recorded and when the DA levels had returned to baseline, the
working electrode would be lowered 500 µm DV 3.5 mm, where a similar volume would
be ejected. This continued every 500 µm until DV 7.5 mm. The working electrode was
then retracted from the brain, the pipette emptied of KCl and replaced with DA (200 µM
in 100 µM AA). The working electrode was then moved to ML +2.5 mm, the meninges
were removed over the left side of the brain and the area cleared of blood. The working
electrode was lowered to DV 3.0 mm and baseline was usually obtained within 20 mins.
A setting of 10 psi and 500 ms was used to eject a small volume of DA to check the
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pipette was not obstructed. The duration and pressure of DA ejection was varied until
the amplitude of DA recorded on the screen was between 1 ∼ 2 µM. After such a peak
was obtained, the working electrode was lowered a further 500 µm, and the performance
was repeated until DV 7.5 mm.
3.2.7 Tissue collection and preservation
After the completion of the recordings, rats were removed from the stereotaxic frame
and sacrificed via cervical dislocation. The head was removed, skull was reflected and
the anterior of the brain was sectioned within 1 min, and placed in a glass vial contain-
ing 20 ml 30% sucrose 10% formaldehyde solution at 4 ◦C until sunk. The tissue was
then immersed in tissue freezing medium and frozen at -20 ◦C until histological process-
ing.
3.2.8 Histology
Frozen brains were mounted onto chucks and sliced at 60 µm with a cryostat (CM1850,
Leica). Sections from the striatum were collected in ice trays containing 1 × PBS. Each
slice of interest was mounted onto glass slides and dried overnight. Slices were dehydrated
and stained with cresyl fast violet (CFV), and dehydrated further, with a final immersion
in xylol prior to being cover slipped. Photographs of each slide were taken with a Canon
Power Shot G10 camera (15 MP) and enlarged on a screen for better tract visibillity.
Since the atlas depths were determined from approx 360 g rats and my rats were
between 75 ∼ 160 g, it was necessary to check that the depth of the different sized rat
brains were similar. Thus 2 fresh brains were harvested from 120 g rats and immediately
chopped with a McIlwane Tissue Chopper (The Mickle Laboratory Engineering Co. Ltd)
at 0.9 mm. Each slice was measured with vernier calipers and photographs were taken
with a Canon Power Shot G10 camera (15 MP) (Fig. 3.8). Fresh brain distances were
scaled to the atlas at 5 AP locations and the location (ST or NAc) of each DV co-ordinate
was determined (Table. B.1 and B.2).
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Figure 3.8 – Measurement of total DV depth from brain of a 120 g rat with vernier calipers
3.2.9 Data Processing
3.2.9.1 Data Exclusion Criteria
The tip of each micropipette was 10 µm in inner diameter, while the working electrodes
tips were 30 µm in diameter. Neither of these tips were clearly visible in the histological
sections. The large tract marks as seen in the histological slices were made by the larger,
tapered portion of the glass micropipette. Since the working electrode was oriented ∼200
µm posterior to the micropipette in each case, the location of measurement was determined
to be 2 frames (Paxinos & Watson, 2005) posterior to the visible tract. The AP location of
each experiment was determined and each depth was grouped to ‘ST’ or ‘NAc’ depending
on its corresponding scaled location on the atlas (Fig. B.3).
The first 8 recordings were not used for analysis, additionally the rats for recordings 11
and 33 died during the baselining period prior to recording. Data points where no response
occurred were discarded. For KCl stimulation experiments, volumes smaller than 100 nl
and larger tha 250 nl were not analysed. For DA uptake experiments, amplitudes smaller
than 0.8 µM and larger than 1.99 µM were not analysed.
The FAST Analysis program was used to calculate the amplitude, T100, T80, T50, Tc,
and Trise parameters.
3.2.9.2 Statistical Analysis
Statistica 9 was used for all analyses. Shapiro-Wilks’ test for normality performed on
raw data showed that the data were non-parametric. After log transformation the data
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remained non-parametric. The Kruskal-Wallis test was used on the original data for strain
comparisons of all parameters. Scatterplots were drawn to determine possible correlations
between rat mass, volume of KCl ejected, amplitude of DA selected and T80. Calibration
slopes of all the electrodes used were found to be parametric and 1-way ANOVA was
performed for strain comparison.
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3.3 Results
3.3.1 A typical DA peak
Although parameters of DA peaks differ between strains and method of stimulation, a
typical DA peak, whether as a result from KCl stimulation of application of exogenous
DA began at ‘baseline’. Stimulation with either KCl or DA lead to a rise in striatal DA
concentration until peak ‘Amplitude’ was obtained. The time (s) from stimulation to
peak amplitude was termed ‘Trise’. From the peak amplitude, the level of DA decreased
to 20%, 50%, 60%, 80% and 100% over time. The ‘T80’ was the time (s) for the DA to
decrease to 80% of the peak amplitude, the ‘T50’ was the time (s) for the DA to decrease
to 50% of the peak amplitude, and the ‘Tc’ was the time (s) for the DA to decrease from
to 20% to 60% of the peak amplitude (Fig. 3.9).
Figure 3.9 – Example of a typical DA peak with amplitude, T80, T50, Tc, T100 and Trise
parameters marked in approximate locations
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3.3.2 Potassium Stimulated release of endogenous dopamine
3.3.2.1 Verification of data
3.3.2.1.1 Analysis of calibration slopes There was no significant strain difference
in the calibration slopes used in the KCl stimulation experiments (Fig. 3.10). This in-
dicated that electrode calibration factors were not significantly different between strains
(Appendix Fig. B.8 ∼ Fig. B.9).
Figure 3.10 – Strain comparison of calibration slopes used in the KCl stimulation experi-
ments; p=0.8281
58
Results Chapter 3. In vivo Chronoamperometry
3.3.2.1.2 Analysis of rat mass There was significant strain difference in rat mass
in the KCl stimulated release experiments. SHR and WKY masses were similar and
significantly lighter than the SDs (Fig. 3.11).
Figure 3.11 – Strain difference in rat mass. SHR and WKY were significantly smaller than
that of SDs, $ p=0.0000, # p=0.0000; Overall: H(2, N=215)=36.2518 p=0.0000
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However, scatterplots showed that the amplitude and T80 parameters of KCl stimulated
release of DA were not dependent on rat mass (Fig. 3.12 and Fig. B.7), and that mass
was not a confounding factor in subsequent analyses.
Figure 3.12 – Scatterplot of KCl stimulated release amplitudes vs rat mass. Outliers ‘a’
and ‘b’ were contributions from Rec 38, SHR; outlier ‘c’ was a contribution from Rec 28,
SD; outliers ‘d’ was a contribution from Rec 39, SHR
Figure 3.13 – Scatterplot of T80 vs rat mass. Outlier ‘a’ was a single contribution from Rec
20, WKY; outlier ‘b’ was a contribution from Rec 30, WKY; outlier ‘c’ was a contribution
from Rec 38, SHR; outliers ‘d’ and ‘e’ were 2 contributions from Rec 28, SD
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3.3.2.1.3 Analysis of KCl ejection volumes The volume of KCl ejection was lim-
ited to between 100 ∼ 250 nl (12 ∼ 30 nmol KCl), but a strain difference was detected
in the ejected volumes (H(2,N=215)=13.6405 p=0.0011), where SHRs received amounts
of KCl on the larger end of the range than SD (Fig. 3.14). This was an anomaly which
should not have occured, however, the amplitudes that were measured were not dependent
on the KCl volumes within this range (Fig. 3.15), which indicated that higher amplitudes
were not solely due to higher volumes of KCl ejections and that the strain difference in
ejection volumes did not compromise subsequent strain comparisons of amplitudes.
Figure 3.14 – Strain difference of KCl ejection volumes. SHR received significantly higher
volumes of KCl than SDs, $ p=0.0009, Overall: H(2, N=215)=13.6405 p=0.0011
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Figure 3.15 – Scatterplot of KCl volumes used vs the amplitude of DA released
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3.3.2.2 Strain difference in the amplitude (µM) of stimulated dopamine re-
lease
Analysis of strain difference of KCl stimulated release amplitudes showed that the SHR re-
leased similar amounts of DA to SD, and both strains released significantly larger amounts
of DA than the WKY (Fig. 3.16). When the ST and NAc areas were analysed separately,
the effect was significant in the ST (H(2, N=157)=17.1049 p=0.0002), but not in the NAc
(H(2, N=30)=5.7272 p=0.0571).
Figure 3.16 – Strain difference in DA peak amplitudes where the SHR and SD released
significantly larger amounts of DA compared to WKY, ∗p=0.0005; # p=0.0031; Overall:
H(2, N=215)=17.4160 p=0.0002; n = 70 datapoints recorded from 8 SHR, n = 81 datapoints
recorded from 8 WKY, n = 64 data points recorded from 7 SD
63
Results Chapter 3. In vivo Chronoamperometry
3.3.2.3 Strain difference in T80 of KCl stimulated release of endogenous DA
The T80 parameter was not dependent on amplitude size (Fig. 3.17) and was thus com-
parable across strains.
Figure 3.17 – No correlation between T80 and amplitudes, r=-0.1754; n = 70 datapoints
recorded from 8 SHR, n = 81 datapoints recorded from 8 WKY, n = 64 data points recorded
from 7 SD
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Strain comparison of T80 showed that SHR and WKY had similar T80 values, that
were both significantly longer than that of SDs (Fig. 3.18). When the ST and NAc were
analysed separately, this pattern was significant in the ST (Fig. 3.19) but not in the NAc
(H(2, N=30)=2.8921 p=0.2355).
Figure 3.18 – Strain difference in T80 of KCl stimulated release of DA. $ p=0.0099, #
p=0.0065; Overall: H(2, N=215)=11.7372 p=0.0028; n = 70 datapoints recorded from 8
SHR, n = 81 datapoints recorded from 8 WKY, n = 64 data points recorded from 7 SD
Figure 3.19 – Strain difference in T80 of KCl stimulated release of DA in the ST region
only. $ p=0.0215, # p=0.0031; H(2, N=157)=11.8774 p=0.0026
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3.3.2.4 Strain comparison of Trise
Strain comparison of Trise showed no significant difference, even though the peak ampli-
tudes were signifcantly different between strains.
Figure 3.20 – Strain comparison of Trise; H(2, N=215)=1.643204 p=0.4397; n = 70 data-
points recorded from 8 SHR, n = 81 datapoints recorded from 8 WKY, n = 64 data points
recorded from 7 SD
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3.3.2.5 Strain comparison of parameters when results were averaged per rat
In the striatum, when all ST points of each rat was averaged to a single mean value, no sig-
nificant strain differences were detected for any parameter: Amplitude H(2, N=23)=1.9216
p=0.3826; T80 H(2, N=23)=3.1150 p=0.2107; Volume H(2, N=23) =1.6066 p=0.4479.
Similar results were observed in the NAc: Amplitude H (2, N=15)=3.2600 p=0.1959;
T80 H(2, N=15)=0.7200 p=0.6977; Volume H(2, N=15)=0.9916 p=0.6091.
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3.3.3 Clearance of exogenously applied dopamine
3.3.3.1 Verification of data
3.3.3.1.1 Analysis of working electrode calibration slopes A comparison of cal-
ibration slopes showed no significant differences between strains (p=0.1098). This indi-
cated that electrode calibration factors were not significantly different between strains
(Appendix Tables B.36 and B.37).
Figure 3.21 – Strain comparison of calibration slopes in the DA clearance experiments;
p=0.1098
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3.3.3.1.2 Analysis of rat mass A comparison of rat mass across strains showed no
differences between strains in the experiments where exogenous DA was applied (Fig. 3.22).
Figure 3.22 – Strain comparison of rat mass in the DA clearance experiments; H(2,
N=306)=1.5009 p=0.4721
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3.3.3.1.3 Analysis of controlled amplitudes of exogenously applied DA Am-
plitudes of exogenously applied DA were controlled between 0.8 µM ∼ 1.99 µM and no
strain differences were observed (Fig. 3.23), indicating that amplitudes were well con-
trolled across strains.
Figure 3.23 – Strain comparison of controlled amplitudes of exogenously applied DA; H(2,
N=306)=2.0867 p=0.3523; n = 95 datapoints recorded from 9 SHR, n = 116 datapoints
recorded from 9 WKY, n = 95 data points recorded from 5 SD
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3.3.3.1.4 Analysis of T80 comparability Scatterplots indicated that the T80 param-
eter was not dependent on the rat mass (Fig. 3.25), or volumes of DA ejected (Fig. 3.24).
Lack of correlations for these factors showed that parameters were comparable across
strains.
Figure 3.24 – Scatterplot of volume vs T80 of responses to exogenously applied dopamine.
Outlier ‘a’ was a single contribution of Rec 15, SD; outliers ‘b’ and ‘c’ were two contributions
from Rec 22, WKY; outlier ‘d’ was a single contribution from Rec 38, SHR
Figure 3.25 – Scatterplot of T80 vs mass of rats used in this experiment. Outlier ‘a’ was
a single contribution from Rec 38, SHR; outlier ‘b’ was a single contribution from Rec 22,
WKY; outlier ‘c’ was a single contribution from Rec 34, SHR
.
71
Results Chapter 3. In vivo Chronoamperometry
3.3.3.2 Strain comparison of T80
The T80 parameter was the time (s) for the concentration of DA to decrease to 80% of
the peak amplitudes that were limited between 0.8 µM ∼ 1.99 µM. A comparison of T80
where the entire range of amplitudes showed no significant differences between strains
(H(2, N=306)=3.5961 p=0.1656). However when the range of amplitudes was separated
into 3 groups for more stringent analysis, strain differences became apparent. Amplitudes
from 0.8 ∼ 0.99 µM were labeled ‘Small’, 1 ∼ 1.5 µM were labeled ‘Medium’ and 1.6 ∼
1.99 µM were labeled ‘Large’.
No strain difference was seen in T80 in the ‘Small’ (Appendix Fig. B.41) or ‘Medium’
amplitude groups (Appendix Fig. B.42), however, significant differences occured in the
the ‘Large’ amplitude group. The SHR T80 was significantly shorter than that of WKY
(p=0.0301) (Fig. 3.26).
Figure 3.26 – Strain difference in T80 in the ‘Large’ amplitude group; H(2, N=61)=6.6896
p=0.0353; ∗p=0.0301; n = 23 datapoints recorded from 9 SHR, n = 23 datapoints recorded
from 9 WKY, n = 15 data points recorded from 5 SD
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3.3.3.3 Strain comparison of T50
No strain difference in T50 was observed when the entire range of amplitudes was analysed
together (H(2,N=306)=3.8139 p=0.1485), however singnificant strain difference was ob-
served in ‘Large’ amplitude group where SHR had the shortest T50 and WKY the longest
(H(2, N=61)=6.4571 p=0.0396 ) (Fig. 3.27).
Figure 3.27 – Strain difference in T50 in the ‘Large’ amplitude group; H(2, N=61)=6.4571
p=0.0396; ∗p=0.0395; n = 23 datapoints recorded from 9 SHR, n = 23 datapoints recorded
from 9 WKY, n = 15 data points recorded from 5 SD
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3.3.3.4 Strain comparison of Tc
Similar to the findings for T80 and T50, the Tc showed no difference when the entire range
of amplitudes was analysed together (H(2, N=306)=4.4758 p=0.1067), however a signifi-
cant strain difference between SHR and WKY was found in the ‘Large’ amplitude group
where SHR had the shortest and WKY the longest Tc (H(2, N=61)=6.5305 p=0.0382)
(Fig. 3.28).
Figure 3.28 – Strain difference in Tc in the ‘Large’ amplitude group; H(2,N=61)=6.5305
p=0.0382; ∗p=0.0331; n = 23 datapoints recorded from 9 SHR, n = 23 datapoints recorded
from 9 WKY, n = 15 data points recorded from 5 SD
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3.3.3.5 Strain comparison for T100
A significant strain effect was seen in T100 where SHR and SD times were similar and both
were smaller than that of WKY (Fig. 3.29).
Figure 3.29 – Strain difference in T100; SHR and SDs had T100s that were similarly shorter
than the WKY ; Overall H(2, N=306)=6.6654 p=0.0357; n = 95 datapoints recorded from
9 SHR, n = 116 datapoints recorded from 9 WKY, n = 95 data points recorded from 5 SD
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3.3.3.6 Strain comparison in the amount of DA required to generate ampli-
tudes within the specified range
A large range of volumes (∼3 nl ∼ >4000 nl) of DA was ejected in order to attain the
required range of DA amplitudes, however a scatterplot showed that the amplitude sizes
were not dependent on the amount of dopamine applied (Fig. 3.30). Thus it was queried
whether there was any strain difference in the amount of DA required to generate the
specified amplitudes.
Figure 3.30 – Scatterplot of volume of DA applied and amplitudes obtained; r=0.0325
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Strain comparison of the volumes that were ejected in order to achieve the required
amplitudes (0.8 ∼ 1.99 µM) showed that the SHR required significantly smaller amounts
of DA than the other strains (Fig. 3.31). This pattern was robust. When the amplitude
groups were analysed individually, all amplitude groups showed significant strain differ-
ences in the same pattern with p<0.001. Specifically, ‘Small’ amplitudes H(2,N=66)=14.0906
p=0.0009, ‘Medium’ amplitudes H(2, N=179)=20.3880 p=0.0000 and ‘Large’ amplitudes
H(2, N=61)=22.8645 p=0.0000. When the ST and NAc areas were analysed separately,
this pattern remained consistent and significant in both the ST and NAc (ST: H (2,
N=254)=37.8390 p=0.0000; NAc: H(2, N=34)=8.9469 p=0.0114).
Figure 3.31 – Strain difference in the volume required to reach amplitudes between 0.8 ∼
1.99 µM; H(2, N=306)=47.6532; ∗p=0.0000; n = 95 datapoints recorded from 9 SHR, n =
116 datapoints recorded from 9 WKY, n = 95 data points recorded from 5 SD
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3.3.3.7 Strain comparison of Trise
Strain comparison of Trise showed that SHR had the shortest and WKY the longest
Trise, with SDs in between (H(2, N=306)=9.8539 p=0.0072). This pattern was seen
most clearly in the ST (Fig. 3.32, but not in the NAc (H (2,N=34)=0.8531). More
specifically, a strain difference was detected in the ST of the ‘Large’ amplitude group
(H(2, N=53)=10.3834 p=0.0056), and not in the smaller amplitude groups (‘Small’: H(2,
N=66)=3.6728 p=0.1594; ‘Medium’: H(2, N=179)=4.0079 p=0.1348).
Figure 3.32 – Strain difference in Trise in the ST; H(2, N=53)=10.3834 p=0.0056
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3.3.3.8 Strain comparison of parameters when results were averaged per rat
In the striatum, when all ST points of each rat were averaged to a single mean value, no
significant strain differences were detected for any parameter: T80 H (2, N=23)=0.0773
p=0.9621; T50 H (2, N=23)=0.0773 p=0.9621; Tc H(2, N=23)=0.5382 p=0.7641; Trise H
(2, N=23)=1.4850 p=0.4759.
Similar results were observed in the NAc:T80 H(2, N=14)=0.7020 p=0.7040 ; T50 H(2,
N=14)=1.2900 p=0.5247; Tc H(2, N=14)=1.4748 p=0.4783; Trise H(2, N=14)=0.0808
p=0.9604.
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3.3.4 Analysis of calibrations
Analysis of 2 calibrations taken prior to and after recordings Rec 39 and Rec 40 showed
that the calibration factors deteriorated slightly during the experiments (Table. 3.1).
However, the electrode parameters after the recordings were still adequate for recordings,
since the LODs were <0.1 µM and selectivities were >100.
Table 3.1 – Calibration parameters prior to and after rat recording numbers 39 and 40
3.4 Discussion
3.4.1 SHR vs WKY
Compared with the WKY, the SHR released significantly larger amounts of DA from
similar KCl ejection volumes, while the T80 clearance times of these stimulated peaks
were similar, and suggested that the WKY clear DA slower than that of SHR. This
was confirmed with the DA clearance of exogenously applied DA experiments, when the
amplitudes were controlled, SHR T80 was significantly shorter than that of WKY, and
contradicts a previous in vitro study that suggested that DAT activity was not impaired
in the SHR (Simchon et al., 2010). The present results suggest that DAT activity is
impaired in the WKY as compared to the SHR in the falling phase of the DA peak.
The volume of exogenously applied DA required to reach the specified amplitude was
significantly lower in the SHR than WKY, and the Trise to the peak amplitudes were
significantly shorter in the SHR. This suggested that the clearance of DA in the SHR is
delayed in the rising phase of the DA application, compared to WKY.
The SHR released significantly larger amounts of DA than WKY and contradicts
previous in vitro superfusion studies that had showed decreased KCl stimulated release of
DA (Russell et al., 1995), and no difference between the strains by in vitro measurement
of synaptosomal release of DA (Simchon et al., 2010). Additionally, these data also
contradict previous in vivo microdialysis results, where KCl stimulated release of DA was
lower in SHR than in WKY (Carboni et al., 2003).
The potassium stimulated results of the present study was similar to only one previous
Japanese in vivo voltammetric study from 1984, which had found that the release of DA
and 5-HT in juvenile SHR ST was more prominent than in WKY, under stress (Ikeda
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et al., 1984). Unfortunately this paper was not accessible via any means from UCT, and
the authors were not contactable in order to obtain further details of the study. It cannot
be determined from the abstract whether the ‘release’ was basal, electrically or KCl stim-
ulated, although it was mentioned to be ‘stress’ stimulated, however the form of stress
is not clear from the abstract. The DA and 5-HT were mentioned together, although it
cannot be determined whether the attempts were to measure each neurotransmitter seper-
ately, or whether the authors were accounting for the lack of selectivity of the electrodes
at the time - however, current electrodes still do not differentiate between DA and 5-HT
adequately. Finally, ‘under stress’ implied that the study was performed on freely moving
animals, while the present study was performed on urethane anaesthetized animals. The
Japanese study suggested that the SHR were more susceptible to stress in the central
monoaminergic systems due to this increased release response in the SHR (Ikeda et al.,
1984). Perhaps stimulated release is larger in SHR in the juvenile stage as seen in the
present study and in the Japanese study, which causes a developmental compensation in
the system that leads to decreased release in the adult stage, as found by the in vivo
and microdialysis studies. Alternatively, the timescale of the voltammetric experiments
measure the effects of the stimulus within seconds, while microdialysis results are an ac-
cumulation of minutes. It is possible that the increased immediate release of DA could
cause decreased further release by action of autoreceptors and resulting in lower release
data from SHR in the microdialysis studies.
3.4.2 SHR vs SD
Compared with the SD, the SHR released similar amounts of DA from KCl stimulations,
while the SD had shorter T80 clearance times from these stimulated peaks. Comparison
of T80 when the amplitudes were controlled showed that the T80s were similar in these
strains. The volume of exogenously applied DA required to reach the required amplitude
was significantly lower in the SHR than SD, while the Trise to the amplitudes were similar.
These results support that although the SHR and SD have similar release and uptake
parameters, the SDs reached the same amplitude with much larger amounts of applied
DA, but in the same amount of time as SHR, suggesting that the clearance of DA in the
SHR could be delayed in the rising phase of the DA application.
No studies have compared KCl stimulated release responses between SHR and SD.
One in vivo microdialysis study had shown that basal DA levels of SHR were lower than
of SD, and that amphetamine stimulated release of DA was higher in SHR than SD
(Heal et al., 2008). However, amphetamine and KCl stimulations are not comparable,
since amphetamine induces vesicular leakage of DA into the presynaptic cytoplasm and
non-vesicular release of DA, while KCl mainly stimulates vesicular release.
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3.4.3 WKY vs SD
Compared with the SD, the WKY released significantly lower levels of DA from KCl
stimulated release, and T80 of these peaks were significantly longer than SD. Comparison
of T80 when the amplitudes were controlled showed that the T80s were in fact longer in
the WKY. The volume of exogenously applied DA required to reach the specified ampli-
tude was significantly lower in the WKY than SD, while the Trise to the amplitudes were
significantly longer than the SDs. These results indicate that the WKY release less DA
and have significantly slower uptake rates than SD, and that the slow uptake rates occurs
both in the rising and in the diminishing phase of the DA response.
Taken together, the present results support that in the rising phase of the DA response,
DAT activity in the SHR is slower compared to both SD and WKY, although the WKY
were slower than the SDs. SHR and SD release similar amounts of DA, while the WKY
released the least. T80s showed that the WKY had the longest clearance times in the
falling phase of the response compared to the other strains.
Strain difference in clearance times were most detectable in the ‘large’ amplitude group
when amplitudes were 1.6 ∼ 1.99 µM. Although strain difference did not reach significance
in the ‘small’ and ‘medium’ size amplitude groups, these groups showed the same patterns
of lowest T80, T50 and Tc times in the SHR, highest in the WKY and SDs in between. It
appears that when DA amplitudes are low, all three strains clear DA similarly, however at
higher amplitudes of DA, the defect in DAT function in the falling phase of the response
becomes more evident in the WKY.
3.4.4 Considerations and controls for possible confounding fac-
tors
3.4.4.1 Lack of correlation beween Mass, volume, amplitude and T80 for ex-
ogenouly applied DA
Scatterplots showed that ejection volumes and rat mass were not correlated with am-
plitude or T80, enforcing that rat mass and volume of exogenous DA applied were not
confounding factors and significant differences observed were strain dependent. Scatter-
plots showed various outliers that were the results from various peaks from various rats
and not attributed to a single rat recording or electrode. Histological examination did
not warrant the exclusion of these points from the analysis.
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3.4.4.2 Analysis of KCl ejection volumes
Although SHR received volumes of KCl on the larger end of the range limit (100 ∼
250 nl) compared to the SDs, the KCl volumes within this range were not correlated
with amplitudes, which indicated that higher amplitudes were not solely due to higher
volumes of KCl and that the slightly higher volumes of KCl received by the SHR did
not compromise subsequent strain comparisons of amplitudes or T80. Additionally, the
SDs that received the lowest volumes of KCl but achieved peak amplitudes that were
more similar to that of the SHR, and the WKY had received similar amounts of KCl
compared to both of these strains, had released the least amount of stimulated DA further
indicating that the strain difference in ejection volumes was not a confounding factor in
these experiments.
3.4.4.3 Rat mass did not influence amplitude and T80 parameters in KCl
experiments
Rat mass was found to be significantly larger in the SDs compared to the SHR and
WKY in the KCl stimulate release experiments which was not found in the DA clearance
experiments. Rat mass was however not correlated with either amplitude or T80, which
indicated that it was not a confounding factor in the analyses.
3.4.5 Analyss of averaged data in the ST and NAc
When individual points from the ST and NAc were averaged for each rat, so that each
rat contributed a single ST and NAc point, no significant difference was observed for any
comparison. One could argue that the data should be averged, since the multiple points
taken from each site are technically dependent samples in that they were taken from the
same rat. However, if this logic is employed to its fullest, the ST and NAc data should in
fact be reduced to a single point, with each rat contributing only one point to the dataset.
However, it is known that different areas in the ST and NAc respond differently, and the
averaging of data points could render the results physiologically meaningless.
3.4.6 Electrode Sensitivity and Selectivity
Electrode calibrations before and after 2 experiments showed that the selectivity had de-
creased slightly. This is could have been due to adsorption of the electrode sites from
previously oxidized material, which gradually decreased the available sites on the elec-
trode that could cause oxidation and conduct signal, also termed bio-fouling. Decreasing
sensitivity and selectivity of the electrodes would be a cause for concern, since it could
cause latter points in the recording to be due to less selective signals, although, since it is
impossible to determine a point at which the bio-fouling occurs, or the gradient of severity
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at which it occurs, it is not possible to correct for the changes in calibration parameters
during or after the experiment. However, the calibration parameters that were observed
after these experiments remained adequate for recordings, and even though the slope of
Rec 40 had increased, the slope after the Rec 40 experiment was similar to that of the
start of the Rec 39 experiment. It appears that the variation between calibrations could
in fact balance the decrease in electrode sensitivity within each experiment.
3.5 Limitations
3.5.1 Non-parametric data
The present data was not parametric, and thus statistical analyses of lower power had
to be employed for comparisons, however the non parametric data could not be avoided,
since amplitude and time parameters were all >0. For clearance time parameters, the
majority of peaks returned to baseline within the first 100 s, although there were some
peaks that took up to 600 s, these could not be justifiably excluded on basis of histology, or
other factors noted on the experimental day. For the amplitude parameter, the majority
of peaks resulting from KCl stimulations were <10 µM, although observations ranged
to ∼60 µM, these outliers could also not be justifiably excluded. Thus, the data was
inevitably skewed toward the left side.
3.5.2 Histological determination of recording location
Histological determination of the exact placement of the electrodes were difficult, since
the glass micropipette diameter leading up to the tip was quite large in comparison to the
small 30 µm tips of the working electrodes and the ∼10 µm tips of the glass electrodes.
A previous study that had compared the difference in DA clearance rates between the ST
and the NAc had passed current was at the end of the experiment to mark the deepest
point of the measurements (David et al., 1998). However this procedure required the use
of a different headstage and was not suggested during training.
3.5.3 Lack of significance in NAc recordings compared to ST
recordings
The majority of comparisons within the NAc showed a lack of significance between strains,
while recordings from the ST tended to follow patterns of the general strain comparisons
that included the NAc. This could have been due to a genuine lack of differences in NAc
responses between strains. However it could have also been due to lower sample sizes of
recordings obtained from the NAc. Histological determination of tracts typically showed
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that the aim was often too lateral and recordings often taken from outside the striatum
or in the anterior commisure and there was no response, which resulted in the exclusion
of these points from the analyses.
Previous studies had only compared differences in responses between the ST and NAc
within strains. Rat ST and NAc DAT were found to have different molecular weights
(Lew et al., 1991, 1992), and differences in molecular weights (and thus possibly function)
between the ST and NAc could explain the differences in clearance rates between the ST
and NAc that were previously observed (David et al., 1998).
3.5.4 Rats surviving under anaesthesia
In some rats, only the KCl or DA recordings could be performed, while others were
used for both types of recordings. This was dependent on whether the rat survived the
recording. Rat body masses did not differ for the DA application experiments, while SDs
in the KCl experiments were heavier than the SHR and WKY. Since the DA application
recordings typically occured after the KCl stimulations, one would assume that the smaller
rats that were not able to survive past the KCl recording thus did not contribute to the
DA recordings. However, the descriptive statistics of rat masses showed that the SD rat
masses were smaller in the DA experiments than in the KCl, suggesting that it was the
larger rats that did not survive the experiments - which was not expected.
Some rats died suddenly during the recordings without any apparent reasons, which
is a cause for concern, since brain responses in the rat could have become errant prior
to death. However observations of rat breathing saw no change in rate or depth, and
deaths were unpredicatable. Thus the last point from these recordings were excluded
from analyses.
Results taken from anaesthetized animals cannot be extrapolated to occurrences in
conscious animals, and further to conscious humans. However data obtained in this man-
ner increases the comparability of the data with other in vivo chronoamperometry studies
performed on anaesthetized rats (Sabeti et al., 2003; Gerhardt and Burmeister, 2000), and
allow assessment of whether this initial set-up was successful. Additionally, it was nec-
essary to show competence in conducting experiments with anaesthetized rats prior to
setting up the technique to perform recordings in awake animals due to increased com-
plexity of the latter. More importantly, it is not possible to perform mapping experiments
on awake animals, since the locations of electrodes implanted into awake animals cannot
be manipulated.
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3.6 Conclusion
The set-up of the in vivo chronoamperometry technique in the Russell laboratory was
successful. This technique, although with certain limitations, was able to detect neu-
rochemical differences between the SHR, WKY and SD rat strains. The present results
showed that the WKY released the least amount of DA and also had the slowest clearance
times compared to the other two strains, while the SHR showed similarities with the SD,
although with a delayed DAT function in the rising phase of the responses.
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4 Behavioural Responses to Methylphenidate
Treatment
4.1 Introduction
Methylphenidate (MPH) has been shown to be useful in the treatment of symptoms of
ADHD. In the SHR model however, MPH produced increased activity in SHR and WKY
in terms of lever presses (Sagvolden et al., 1993b), as well as exploratory behaviour in
the open field as well as in the operant chamber during a test of visual spatial atten-
tion (Wultz et al., 1990; Thanos et al., 2010). Although sub-chronic methylphenidate
treatment decreased rearing activity of the SHR in the Làt-maze (Aspide et al., 2000).
Currently no known studies have been published regarding SHR activity in voluntary
running wheels. Measurement of wheel revolutions produced by rats housed in cages
with attached running wheels could allow accurate measurement of voluntary activity
and possibly provide a valuable strain comparative measure.
Since low dose MPH appears to ameliorate while high doses potentiates ADHD symp-
toms, the present study tested low oral doses of MPH from 0.5 to 5 mg/kg in the SHR for
4 days each in order to determine the optimum dose at which MPH affects SHR behaviour.
4.2 Methods
4.2.1 Animals
Animals were born in the main UCT Animal Unit where food and water was available
ad libitum, temperature was controlled between 22 ∼ 24 ◦C and a 12 hr light/dark cycle
(06:00 lights on) was maintained. At P 21 pups were weaned and transferred to the
satellite Animal Facility in the Anatomy Building where temperature and food availability
were controlled as above, but the 12 hr light/dark cycle was altered (09:00 lights off). Rats
were kept with littermates and allowed to acclimatize to the new light/dark cycle for 1
week prior to commencement of experiments at P 28. From P 24 ∼ P 27 rats were placed
in individual cages for 30 mins each day and were given condensed milk vehicle (CM) in
petri-dishes. All rats readily consumed vehicle by P 27. A total of 11 SHR and 7 WKY
were used. This experiment was approved by the UCT Faculty of Health Sciences Animal
Research Ethics Committee. Project number: 008/005.
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4.2.2 Running Wheels
SHRs were randomly assigned into treated (SHRM) and non-treated (SHR) groups, while
WKY served as strain comparison controls and were not treated. At P 28, rats were
placed into individual cages with attached running wheels. In dosing period 1 (P 28 ∼
P 31), vehicle was administered to all groups. In dosing periods 2 ∼ 5 (P 32 ∼ P 35;
P 36 ∼ P 39; P 40 ∼ P 43; P 44 ∼ P 47) SHRM received 0.5, 1.0, 2.0 and 5.0 mg/kg
MPH respectively, while SHR and WKY groups received vehicle. Vehicle or drug was
administered twice a day, at the start and 6 hrs into the dark cycle (09:00 and 15:00),
since the half-life of MPH is approximately 2.5 hours. In dosing period 6 (P 48 ∼ P 51)
no vehicle or drug was administered to any groups of rats.
Revolutions were recorded via an automated computer system (Exercise Wheel Data
Capturer, RRE v1.2). Each revolution was equivalent to a distance of 1 m.
4.2.3 Statistical Analysis
Dark and light cycle revolutions over each dosage period were averaged for each rat.
Shapiro-Wilks’s Normality tests (Statistica 9) revealed that the data were not parametric
(Fig. ??). Kruskal-Wallis and Dunn’s Multiple Comparison tests were used for all group
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4.3 Results
4.3.1 Running revolutions during dosage period 1: Vehicle ad-
ministration only
In the first dosage period when vehicle was administered to all groups, there was no sig-
nificant difference in running revolutions between groups during the dark cycle (Fig. 4.1).
However during the light cycle, the SHR and SHRM groups ran significantly more revo-
lutions than the WKY (Fig. 4.2).
Figure 4.1 – Average number of revolutions of running wheels during dark cycles when ve-
hicle was administered to all groups; No significant difference between groups was observed;
H(2, N=18)=5.913617 p=0.0520; SHR n=6, SHRM n=5, WKY n=7
Figure 4.2 – Average number of revolutions of running wheels during light cycles when
vehicle was administered to all groups; WKY ran significantly fewer revolutions than SHR
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4.3.2 Running revolutions during dosage period 2: 0.5 mg MPH/kg
for treated group
During dosage period 2, MPH was administered at 0.5 mg/kg to the SHRM. The WKY
ran significantly fewer revolutions than SHRM in both dark and light cycles, and also
ran less than SHR during the light cycle (Fig. 4.3 and Fig. 4.4). No difference in running
distance was detected between SHRM and SHR groups, indicating no effect of MPH
treatment.
Figure 4.3 – Average number of revolutions of running wheels during the dark cycle when
SHRM received 0.5 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
(p=0.0487), and had a tendency to run fewer revolutions than SHR (p=0.0950); H(2,
N=18)=7.2610 p=0.0265; SHR n=6, SHRM n=5, WKY n=7
Figure 4.4 – Average number of revolutions of running wheels during the light cycle when
SHRM received 0.5 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
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4.3.3 Running revolutions during dosage period 3: 1.0 mg MPH/kg
for treated group
Dosage period 3 when MPH was administered at 1.0 mg/kg showed the same pattern as
dosage period 2. The WKY ran fewer revolutions than SHRM in the dark cycle, and ran
fewer revolutions than both SHR and SHRM in the light cycle (Fig. 4.5 and Fig. 4.6). No
effect of MPH treatment was detected.
Figure 4.5 – Average number of revolutions of running wheels during the dark cycle when
SHRM received 1.0 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
(p=0.0047); H(2, N=18)=10.5627 p=0.0051; SHR n=6, SHRM n=5, WKY n=7
Figure 4.6 – Average number of revolutions of running wheels during the light cycle when
SHRM received 1.0 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
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4.3.4 Running revolutions during dosage period 4: 2.0 mg MPH/kg
for treated group
During dosage period 4 when MPH was administered at 2.0 mg MPH/kg, WKY ran
significantly fewer revolutions than SHRM in both dark and light cycles, and also ran less
than SHR during the light cycle (Fig. 4.7 and Fig. 4.8). No difference in running distance
was detected between SHRM and SHR groups, indicating no effect of MPH treatment.
Figure 4.7 – Average number of revolutions of running wheels during the dark cycle when
SHRM received 2.0 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
(p=0.0040), and had a tendency to run fewer revolutions than SHR (p=0.0913); H(2,
N=18)=11.00301 p=0.0041; SHR n=6, SHRM n=5, WKY n=7
Figure 4.8 – Average number of revolutions of running wheels during the light cycle when
SHRM received 2.0 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
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4.3.5 Running revolutions during dosage period 5: 5.0 mg MPH/kg
for treated group
Group comparison of revolutions run during dosage period 5, 5 mg MPH/kg, was similar
to that of previous dosage periods. WKY ran significantly fewer revolutions than SHRM,
and had a tendency to run fewer revolutions than SHR in the dark cycle (Fig. 4.9). WKY
ran less than both SHR and SHRM in the light cycle (Fig. 4.10). No effect of MPH was
found.
Figure 4.9 – Average number of revolutions of running wheels during the dark cycle
when SHRM received 5.0 mg MPH/kg; WKY ran significantly fewer revolutions than
SHRM (p=0.0359), and had a tendency to run fewer revolutions than SHR (p=0.0842);
H(2,N=18)=7.800 p=0.0202; SHR n=6, SHRM n=5, WKY n=7
Figure 4.10 – Average number of revolutions of running wheels during the light cycle when
SHRM received 5.0 mg MPH/kg; WKY ran significantly fewer revolutions than SHRM
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4.3.6 Running revolutions during dosage period 6: No vehicle
or drug administration for all groups
When no substances were administered to any group during dosage period 6, no group
difference in running was found during the dark cycle (Fig. 4.11). A strain difference
in running was found between the SHR and WKY controls in the light cycle, where the
WKY ran significantly less than the SHR, and had a tendency to run less than the SHRM
group (Fig. 4.12).
Figure 4.11 – Average number of revolutions of running wheels during the dark cycle when
no substances were administered to all groups; No group differences in running distances
were observed; H(2,N=18)=5.3489 p=0.0689; SHR n=6, SHRM n=5, WKY n=7
Figure 4.12 – Average number of revolutions of running wheels during the light cycle
when no substances were administered to all groups; WKY ran significantly less than SHR
(p=0.0406) and had a tendency to run less than SHRM (p=0.0538); H(2,N=18)=8.1392
p=0.0171; SHR n=6, SHRM n=5, WKY n=7
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4.4 Discussion
The purpose of this experiment was to determine whether the use of cages with attached
running wheels could be useful as a strain comparative measure, and to find a dose of
MPH that could decrease the running activity in SHR to a level that is more similar to
WKY.
Significant difference in running revolutions were consistently observed between the
SHR and WKY during the light cycles but not the dark cycles. This suggests that volun-
tary running during the light cycle, in cages with attached running wheels, could be used
to differentiate between SHR and WKY strains.
During the dark cycle, the SHRM ran significantly more than WKY at every dosage
period where MPH was administered, and not in the vehicle and non-treated periods. Al-
though no significant differences in running was measured between the SHR and SHRM,
when compared to the WKY, the SHRM ran more while the SHR did not, suggesting
that MPH could be increasing voluntary activity levels in the SHRM group that was
not detectable in direct comparison with the SHR at the present sample sizes. These
results are in line with studies that have shown increased activity levels as a result of
MPH treatment. In the open field test, MPH increased exploratory behaviour of both
SHR and WKY (Wultz et al., 1990; Barron et al., 2009). Locomotor activity in the op-
erant chamber of a visual stimulus position discrimination task increased in both SHR
and WKY (Thanos et al., 2010), and number of lever presses increased as a response
to MPH treatment in a delay-of-enforcement task for both SHR and WKY (Sagvolden
et al., 1993b). Thus is terms of general motor activity, MPH has an apparent stimula-
tory effect in SHR and no dose was found to decrease their activity levels to that of the
WKY.
The effects of MPH on reducing hyperactivity in children could be due to improve-
ments in top-down regulation of motor control. MPH has been shown to inhibit both DAT
and NET (Markowitz et al., 2006) and the increase in NE levels in the PFC (Kuczen-
ski and Segal, 1997, 2001) was also shown to increase the intrinsic excitability of PFC
neurons, that was mediated through the α2-adrenoreceptor (Andrews and Lavin, 2006;
Arnsten and Dudley, 2005). The effect of MPH on rat cognitive function appears more
promising in the literature. MPH treatment was shown to increase the effectiveness of
a delayed enforcer in both the SHR and WKY, although the response was less promi-
nent in the SHR (Sagvolden et al., 1993b), and sub-chronic MPH treatment was shown
to decrease rearing activity of the SHR in the Làt-maze, a behaviour that is consid-
ered as a reflection on impulsivity (Aspide et al., 2000). Thus perhaps MPH decreases
elements of motor impulsivity that can be measured with specific tasks when reinforce-
ments are clear, however general activity in the SHR that are elicited by unintended
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stimuli (Johansen et al., 2002) may not be affected. In children with ADHD, exces-
sive activity is discouraged while lower levels of activity are reinforced socially, thus
reinforcers for motor activity are clear. However, ‘social appropriateness’ of locomo-
tor activity in rats cannot be determined, thus, if MPH functions by increasing the ef-
fectiveness of reinforcers (Johansen et al., 2002), it could be reasonably expected that
voluntary activity in the running wheels would not decrease as a result of MPH treat-
ment.
4.5 Limitations
Condensed milk was used as the vehicle in this experiment. Even with dilution with
dH2O, the sugar content was likely to still be quite high. It was possible that sucrose
could have different effects in SHR and WKY and induced the increase in activity in
the SHR more than WKY. However, the SHRM only ran significantly more than WKY
during dosage periods where MPH was administered, and not in the vehicle and non-
treated periods, the SHR ran significantly more than the WKY during the light cycle
when vehicle was not administered and the pattern of activity in dosage period 6 when
no vehicle was administered to any of the groups was identical to that seen in dosage
period 1 when condensed milk was administered to all groups. These results suggest that
condensed milk did not cause differential effects on the two strains, although groups of
SHR and WKY without CM/high sucrose administration are required to confirm this
assumption.
Isolation stress could impact on voluntary running behaviour. All the rats were kept in
identical individual cages, which relatively controls for isolations stress, however the SHR
and WKY have been shown to have differential levels of responses to stress, which may
have impacted on the amount of voluntary running between the strains. Unfortunately,
it is difficult to measure accurate activities of individual animals if they were housed in
groups. Perhaps an alternative protocol could be used in which the rats were housed
in groups for the majority of the day and only placed in the wheels for measurement of
voluntary activity for a few hours every night. However this protocol could potentially
enhance the experience of isolation, since the rats never becomes accustomed to it, and
additional handling (since rats would be removed from the wheels each day) could induce
a different form of unquantifiable stress.
The light/dark cycle of animals was changed from 06:00 lights on to 09:00 lights off
from P 21, since the short half life of MPH warrants dosing twice during the dark cycle,
and it was not feasible to administer the 2nd dose of MPH at midnight for each experi-
mental day. The change in light cycle could have been a potential stressor, however the
rats were given 7 days to acclimatize to the new light/dark cycle prior to commencement
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of experimentation, and residual effects of this stress was minimized.
Different doses of MPH were given to the same rat at increasing ages and duration
in the wheels. The previous administrations of MPH could possibly influence the ef-
fects of the subsequent doses due to drug sensitization, which has been shown to occur
in 0.6 mg MPH/kg in adult rats and 2 mg MPH/kg (i.p.) for adolescent as well as
adult SHR (Barron et al., 2009). However, i.p. drug administration has been shown
to cause sensitization more readily than low oral doses of MPH that are therapeutically
relevant to those given to children (Kuczenski and Segal, 2002; Arnsten and Dudley,
2005).
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5.1 Introduction
As reviewed in the introduction, guanfacine’s positive effects in the treatment of ADHD
symptoms and low side effect profile led to FDA approval for its use in treating ADHD in
September, 2009 (May and Kratochvil, 2010). In the SHR, guanfacine treatment at 0.6
mg/kg i.p. showed improvements in sustained attention and reduced hyperactivity and
impulsiveness (Sagvolden, 2006).
This project elected to study the effect of guanfacine on voluntary running in order to
compare drug effects with that of methylphenidate. In addition, activity in the open field
was analysed for the effect of isolation stress in the running wheels. The vehicle for drug
administration was changed from CM to raspberry flavoured jelly to minimize possible
effects of the high sucrose content in the CM.
5.2 Methods
5.2.1 Animals
Animals were trasnferred to the satellite Animal Facility in the Anatomy Building at P
21. Food and water was available ad libitum, temperature was controlled between 22 ∼
24 ◦C and a 12 hr light/dark cycle (06:00 lights on) was maintained. Rats were kept
with littermates when not in running wheels. Rats of each strain were randomly as-
signed to control (SHRC, WKYC or SDC) or guanfacine treated groups (SHRG, WKYG
or SDG). On P 21 and P 22 rats were placed in individual cages for 30 mins and were
given raspberry flavoured jelly vehicle in small petri dishes at 18:00. From P 23 ∼ P 27
Control animals received vehicle and dH2O while Treated animals received vehicle and
guanfacine (HCl salt, Sigma-Aldrich) at 0.69 mg/kg (0.6 mg/kg free base (Sagvolden,
2006)) once a day at 18:00, since the half life of guanfacine is approximately 17 hrs. Rats
were placed in individual cages for the brief period of dosing and returned immediately
to the home cage. An open field test was conducted on P 28, after which rats were
placed in cages with attached running wheels from P 28 ∼ P 32. Dosing continued once
a day while rats were in cages with attached running wheels. Rats were removed from
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running wheels on P 33 and housed with original litter mates until P 35 when another
open field test was performed. Rats were kept with littermates for 2 more days prior
to dissection of PFC, ST, dorsal HIP and ventral HIP for future proteomics studies. A
total of 18 SHR, 13 WKY and 11 SDs were used. This experiment was approved by the
UCT Faculty of Health Sciences Animal Research Ethics Committee. Project number:
009/005.
5.2.2 Running Wheels
Animals were placed into individual cages with attached running wheels from P 28 ∼ P
32 where vehicle and dH2O or guanfacine was administered in petri dishes once a day at
18:00. Running revolutions were recorded via an automated computer system (Exercise
Wheel Data Capturer, RRE v1.2). Each revolution was equivalent to a distance of 1 m.
5.2.3 Open Field
Rat behaviour in the open field was measured on P 28 prior to being placed into running
wheels and on P 35, 2 days after rats were removed from running wheels and rehabituated
with littermates for 2 days prior to open field recordings. On recording days, rats were
brought to the open field room and allowed to habituate to the new environment for 1 hr
prior to recordings. The open field apparatus consisted of a 1 m × 1 m black box. The
‘inner zone’ was the 70 cm × 70 cm area in the middle of the box starting 15 cm away
from the aparatus walls. The ‘outer zone’ was the area between the outer walls of the
apparatus and the ‘inner zone’. After the 1 hr habituation period, each rat was placed
in the outer zone of the open field, facing the right wall and activity was recorded for 15
min in the light cycle using mounted HD cameras (Sony). Faecal pellets of each rat were
counted after each recording, the field was first cleaned with paper towelling and then
wiped with 70% EtOH and left to dry for 20 s prior to recording the activity of the next
rat.
5.2.4 Statistical Analysis
Running Wheel data. Dark and light cycle wheel revolutions were averaged over the 4 run-
ning days for each rat. Shapiro-Wilks’ nomality test was performed and non-parametric
statistics were used (Fig. D.1). Kruskal-Wallis tests were used for comparison of multiple
groups. Mann-Whitney U tests were performed for comparisons within each strain or
treated and non-treated animals. Results are reported in median and quartile range.
Open Field data. Behavioural videos were analysed with Ethovision XT7 software
(Noldus). Unfortunately several videos were corrupted during data transfer, resulting in
very small sample sizes for the SD and WKY strains (SDC n=2, SDG n=1; WKYG n=6;
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WKYC n=3; SHRG n=10; SHRC n=8). Total Distance travelled, average velocity and
times spent in the inner zones before and after placement in running wheels were com-
pared. Data were not parametric. The Wilcoxon matched pairs test was used to compare
before and after placement in the running wheels. Mann-Whitney U test was used to
compare the effect of guanfacine treatment on open field parameters in SHR. Results are
reported in median and quartile range.
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5.3.1.1 Strain comparison of running activity in the dark and light cycles
Strain comparison of running differences in the vehicle treated groups showed that the
SHR ran significantly more than both the WKY and SD strains in both the dark and
light cycles (Fig. 5.1 and Fig. 5.2).
Figure 5.1 – Average number of revolutions of running wheels during dark cycles in control
groups; SHRC ran significantly more than WKYC (p=0.0064) and SDC (p=0.0075); H(2,
N=19)=13.2116 p=0.0014; SHRC n=8, WKYC n=6, SDC n=5
Figure 5.2 – Average number of revolutions of running wheels during light cycles in control
groups; SHRC ran significantly more than WKYC (p=0.0017) and SDC (p=0.0290); H(2,
N=19)=13.6289 p=0.0011; SHRC n=8, WKYC n=6, SDC n=5
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5.3.1.2 Strain comparison of effect of guanfacine treatment on running ac-
tivity in the dark and light cycles
The SHRG ran significantly more than WKYG and SDG during the dark cycle (Fig. 5.3).
During the light cycle however, SHRG ran significantly more than SDG, but not WKYG
(Fig. 5.4). This suggests that guanfacine treatment may have increased WKY activity,
although WKYG running levels was not significantly different from that of SDG (Fig. 5.4).
Figure 5.3 – Average number of revolutions of running wheels during dark cycles in treated
groups; SHRG ran significantly more than WKYG (p=0.0158) and SDG (p=0.0024); H(2,
N=23)=13.7946 p=0.0010; SHRG n=10, WKYG n=7, SDG n=6
Figure 5.4 – Average number of revolutions of running wheels during light cycles in treated
groups; SHRG ran significantly more than SDG (p=0.0095) but not WKYG (p=0.2283);
H(2, N=23)=9.1511 p=0.0103; SHRG n=10, WKYG n=7, SDG n=6
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5.3.1.3 Effect of guanfacine on running levels within each strain
No significant effect of guanfacine treatment was found for any of the strains, during the
dark or light cycles (Fig. 5.5 ∼ Fig. 5.10).
Figure 5.5 – Average number of revolutions of running wheels during dark cycles of SHRC
and SHRG; p=0.5148; SHRC n=8; SHRG n=10
Figure 5.6 – Average number of revolutions of running wheels during light cycles of SHRC
and SHRG; p=0.2743; SHRC n=8; SHRG n=10
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Figure 5.7 – Average number of revolutions of running wheels during dark cycles of WKYC
and WKYG; p=0.3660; WKYC n=6; WKYG n=7
Figure 5.8 – Average number of revolutions of running wheels during light cycles of WKYC
and WKYG; p=0.2343; WKYC n=6; WKYG n=7
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Figure 5.9 – Average number of revolutions of running wheels during dark cycles of SDC
and SDG; p=0.7922; SDC n=5; SDG n=6
Figure 5.10 – Average number of revolutions of running wheels during light cycles of SDC
and SDG; p=0.4286; SDC n=5; SDG n=6
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5.3.2 Open Fields
5.3.2.1 Strain comparison of activities in the open field test
Prior to placement in cages with attached running wheels, the SHR and SD behaved
similarly in the open field test, where both strains moved greater distances (Fig. 5.11),
spent more time in the Inner Zone (Fig. 5.12) and had higher number of entries into the
Inner zone (Fig. 5.13) than the WKY.
Figure 5.11 – Strain comparison of total distance moved in the open field before placement
in running wheels; # p=0.0171; SHR n=18, WKY n=9, SD n=3
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Figure 5.12 – Strain comparison of total duration in the Inner Zone of the open field before
placement in running wheels; ∗p=0.0039; SHR n=18, WKY n=9, SD n=3
Figure 5.13 – Strain comparison of total number of entries into the Inner Zone of the open
field before placement in running wheels; ∗p=0.0001; SHR n=18, WKY n=9, SD n=3
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After the rats had been in the running wheels, the total distance travelled by the SHR
decreased to levels that were similar to the WKY and significantly lower than the SD
(Fig. 5.14), but the time spent in the Inner Zone and number of entries into the Inner
Zone were similar in the SHR and SD, and both were significantly greater than for WKY
(Fig. 5.15 and 5.16)
Figure 5.14 – Strain comparison of total distance moved in the open field after placement
in running wheels; # p=0.0069, $ p=0.0406; SHR n=18, WKY n=9, SD n=3
Figure 5.15 – Strain comparison of total duration in the Inner Zone of the open field after
placement in running wheels; # p=0.0003, ∗p=0.0048; SHR n=18, WKY n=9, SD n=3
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Figure 5.16 – Strain comparison of total number of entries into the Inner Zone of the open
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Strain comparison of only the control groups revealed no differences between the strains
for distances travelled or duration spent in the Inner Zone, but the SHR had significantly
higher number of entries into the Inner Zone than the WKY (Fig. 5.17).
Figure 5.17 – Strain comparison of total number of entries into the Inner Zone of the open
field after placement in running wheels for non treated groups only; ∗p=0.0429; SHR n=8,
WKY n=3, SD n=2
5.3.2.2 Effect of guanfacine treatment in SHR and WKY
No effect of guanfacine treatment was detected in any open field parameter except for a
tendency for the treated group to spend more time in the inner zone after placement in
running wheels (p=0.083139) (Table. D.15). The WKYG spent significantly less time in
the Inner Zone compared to the the WKYC before placement into the running wheels




Chapter 5. Behavioural Responses to Guanfacine
Treatment
5.3.2.3 Effects of SHR being placed in running wheels
5.3.2.3.1 Total distance covered in the open field The total distance covered in
the open field by the both the control and treated SHR was significantly lower after they
had been in the running wheels (Fig. 5.18 and Fig. 5.19).
Figure 5.18 – Comparison of total distance covered before and after placement in running
wheels in control SHR; n=8; ∗p=0.0117
Figure 5.19 – Comparison of total distance covered before and after placement in running
wheels in treated SHR; n=10; ∗p=0.0069
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5.3.2.3.2 Total duration spent in Inner Zone The total duration of time spent
in the Inner Zone of the open field was significantly lower after placement in the running
wheels in the SHR control group, but not in the SHR treated group (Fig. 5.20 and
Fig. 5.21).
Figure 5.20 – Comparison of total duration in inner zone before and after placement in
running wheels in control SHR; n=8; ∗p=0.0117
Figure 5.21 – Comparison of total duration in inner zone before and after placement in
running wheels in treated SHR; n=10; p=0.7989
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5.3.2.3.3 Total number of entries into Inner Zone The total number of entries
into the Inner Zone was lower in both the control and treated SHR groups after placement
in the running wheels (Fig. 5.22 and Fig. 5.23).
Figure 5.22 – Comparison of Frequency of entry into inner zone before and after placement
in running wheels in control SHR; n=8; ∗p=0.0117
Figure 5.23 – Comparison of Frequency of entry into inner zone before and after placement
in running wheels in treated SHR; n=10; ∗p=0.0593
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5.4 Discussion
The non-treated SHR in this experiment ran significantly more than both the non-treated
WKY and SD in the light and dark cycles. In the previous chapter, the vehicle treated
SHR did not run significantly more than the WKY in the dark cycle, but only in the light
cycle. Taken together with the previous results, it appears that the use of CM in the
MPH experiments had increased the WKY activity levels in the dark cycle, since the jelly
vehicle for the guanfacine experiments contains much lower levels of sucrose than the CM
that was used in the MPH experiments. These results indicate that voluntary running
activity could potentially be a measure with which to differentiate between strains if no
substances or an appropriate vehicle is administered.
The treated SHR ran significantly more than the WKYG and SDG during the dark cy-
cles, but no effects of guanfacine treatment on SHR voluntary activity levels were detected.
These results contradict that of a previously published study that used the same dose of
guanfacine via i.p. administration and showed that guanfacine decreased hyperactivity in
SHR to levels that were similar to that of WKY (Sagvolden, 2006). The ‘hyperactivity’
in the previous study was measured by the total number of lever presses in a Random
Interval/Extinction schedule experiment, where reinforcers were given within 180 s when
the correct lever was pressed, while the incorrect lever resulted in an Extinction schedule
(Sagvolden, 2006). The activity levels in the SHR in the lever pressing experiments were
shaped by the presence of reinforcers and extinction schedules, much like that of children
in social environments. Thus the hyperactivity as measured by the lever press experiment
cannot be directly compared with the present activity in the voluntary running wheels,
since there were no reinforcement or extiction schedules of any kind in this experiment.
Thus according to Sagvolden’s hypothesis of overactivity being due to a failure in the
extinction of responses, without the application of extinction processes for decreasing
activity, it appears that drugs alone cannot decrease the hyperactivity in the SHR.
In the light cycle, the WKYG ran similarly to that of SHRG, suggesting a possible
increase in running activity, even though direct comparison of WKYC vs WKYG showed
no significant difference. Whether the treated WKY group increased in locomotor activity
could not be confirmed, however an increase in WKY as a result of guanfacine treatment
would be interesting, since the WKY have been proposed to have low levels of arousal, on
the left side of the upside-down U curve of arousal controlled by catecholamine imbalance
(Arnsten, 2009), causing their typically low activity levels. Guanfacine administration
could enhance the efficiency of NE transmission in the WKY PFC and generally increase
arousal levels, and lead to higher voluntary activity levels.
Strain comparison of activities in the open field test showed that the WKY were the least
mobile and the most anxious of the three strains, before or after their placement in the
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running wheels. After their placement in running wheels, the SHR had spent less time
in the Inner Zone than the SDs. These results agreed with previous forced exploration
open field studies that found the SHR to be more active than the WKY (van den Buuse
and de Jong, 1988), and that the SDs were more active than the SHR (Sagvolden et al.,
1993b). Several files were corrupted during transfer and the sample size for the SD open
fields were very low (n=3), however the patterns of activity suggest that the present
results were similar to that of the previous study (Sagvolden et al., 1993b). Another
study that measured open field activity of SHR, WKY and SD found that all 3 strains
exhibited similar amounts of activity in the day time (Yang et al., 2006), which contradicts
the present results that were also obtained during the light cycle, but showed marked
lower activities in the WKY compared to the other strains, with or without guanfacine
treatment.
Open field tests in the SHR before and after rats were in the running wheels showed a
general pattern of decreased activity after being in the running wheels, and no difference
between the treated and non-treated groups were observed. However, duration in the
inner zone for the SHRG were not significantly different before and after placement in
running wheels, and a direct comparison of the treated and non-treated SHR revealed a
tendency for an increase in time spent in the Inner Zone after placement in the running
wheels for the SHRG, suggesting that anxiety levels were lower in the treated group of
SHR compared to the non-treated group. For the treated WKY, duration in the inner
zone was significantly lower, and frequency to enter the inner zone had a tendency to
be lower than the WKYC group before placement in the running wheels. The rats were
treated for a week prior to the first open field measurement, and these results suggest
that guanfacine could have induced higher levels of anxiety in the treated WKY compared
with WKYC. However these parameters were not significantly different after the running
wheels, suggesting that the experience of being in the running wheels could have reduced
anxiety levels in the WKY. The apparent increases in time spent in the inner zone for
both the SHR and WKY after placement in the running wheels suggests that exploratory
behaviour increased, possibly as a result of isolation in the running wheels, but it could
have also occured as a result of an increase in age. The first open field measurements were
taken on P 28, and the second measurements was taken on P 35, which both fall within the
prepubertal phase of rat development, however exploratory bahaviour differences between
these two time points have never been compared. A separate experiment that does not
involve the measurement of voluntary running would be required to determine whether
the differences in behaviour after the placement in running wheels was an age effect or
a running wheel effect. In fact, considering that the rats were re-habituated with their
original littermates for 2 days after they were removed from the running wheels, the
differences in open field activites between the 1st and 2nd measurements were most likely
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due to age effects.
Activity in the open field test has been used to measure activity and anxiety (Goto
et al., 1993). The use of this technique for the measurement of hyperactivity in the SHR
has been criticized since increased activity could also be a reflection on decreased anxiety,
which is not a behavioural characteristic of ADHD. In addition, other aspects of ADHD
like impulsiveness and poor sustained attention are difficult to assess in the open field
and are difficult to standardise for translational research in humans. Thus construct and
predictive validities are impossible to obtain in open fields. Additionally, open field results
were found to be sensitive to factors such as light conditions, size of the open field and
duration of testing, which make the data difficult to interpret (Sagvolden et al., 1992a)
and could explain the discrepancy between the present results and the Yang et. al study.
Similar to the results of the previous chapter, where the rats showed no effect of MPH
treatment on distances covered in the running wheels, guanfacine produced no pronounced
effects on the behavioural parameters used in the running wheel and open field tests in
the present chapter. In retrospect, this result should have been expected, since MPH has
been shown to inhibit both DAT and NET (Markowitz et al., 2006) and the increase in
NE levels in the PFC (Kuczenski and Segal, 1997, 2001) was also shown to increase the
intrinsic excitability of PFC neurons, that was mediated through the α2-adrenoreceptor
(Andrews and Lavin, 2006; Arnsten and Dudley, 2005). Thus the effects of both MPH and
guanfacine on behaviour occurs through reinforcement-dependent, top-down regulation by
the PFC, which cannot be measured by use of either the running wheel, or the open field
tests.
Nevertheless, even though the motivation for activities in the open field, like that of
voluntary running, are unknown, the patterns of activies of unknown motivation between
the strains were similar across the tests, where the WKY showed consistently lower activity
levels than the SHR and SDs. This suggests that voluntary running behaviour, and
behaviour in the open field test can be used to measure general and intrinsic activity
patterns within strains that are unaltered by any training protocols.
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6 General Conclusions
The main aim of the present project was to set-up the in vivo chronoamperometry
technique in South Africa, and compare the dopamine release and uptake responses be-
tween the SHR, WKY and SD rat strains. The technique was successfully set-up and
results showed that the SHR released the most amount of DA from controlled potassium
stimulation, the WKY released the least from similar stimulations, while the SDs release
moderate amounts of DA in comparison. Since the SHR had the shortest Trise times and
required the least amount of applied DA to obtain similar amplitudes as the other rat
strains, the results support that the SHR have decreased DAT activity in the rising phase
of the DA peaks in comparison to the WKY and SD. The WKY showed decreased DAT
activity in the falling phase of the DA peaks in comparison to the SHR and SD. The
WKY also showed lower DAT activity in the rising phase of the DA peak when compared
with the SDs. When DA amplitudes were low, all three strains clear DA at similar rates,
however at higher amplitudes of DA, the defect in DAT function in the falling phase of
the response becomes more evident in the WKY. These dopaminergic responses suggest
that DAT activity in the WKY is most impaired compared to the SHR and SD, and that
vesicular DA release in the SHR is not impaired, as suggested by previous in vitro studies.
The SHR were significantly more active than WKY in terms of voluntary behaviour
in cages with attached running wheels and in the open field. These results showed that
strain differences in voluntary behaviour could be measured with the cages with attached
running wheels and the open field test.
Neither guanfacine nor methylphenidate produced significant changes in activity in
voluntary running in cages with attached running wheels or in the open field. The results
suggest that drug administration alone does not decrease voluntary activity, and has no
effect on behaviours that are not controlled by reinforcer and extinction protocols.
The DNA screening results indicated a possible cross between the SHR and SD strains,
although additional genetic screening is required to confirm this suggestion, since the
results of this project found significant differences between the SHR and SD, as well as
significant differences between the SD and WKY, indicating that the neurochemical and
behavioural differences between the strains were not completely abolished. However the
present results suggest that new animal stocks should be purchased for future studies.
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A DNA screening at 3 SNP loci
A.1 Primer Sequences
The 3 pairs of primers defined SNP products of different sequences and expected size
shifts of approximately 10 bp between the SHR and WKY.
The following primer pairs were manufactured by Whitehead Scientific:
D1RAT47 Forward: 5’ - GCC TTG GGA ACC ACA TA - 3’
D1RAT47 Reverse: 5’ - AGG AGT TTG GGA GAC ACC CT - 3’
Expected band size, approximately 162 bp
D2RAT62 Forward: 5’ - CAA GGC CCT TAG CTT CCT G - 3’
D2RAT62 Reverse: 5’ - CCC CCT GTC CTT TAT CTT GC - 3’
Expected band size, approximately 166 bp
D3RAT24 Forward: 5’ - GCC ATG ATA TTG CAC CAT GA - 3’
D3RAT24 Reverse: 5’ - GAC AAG GTC TTT GAT AGA TCC TCA - 3’
Expected band size, approximately 151 bp
Primer pellets were reconstituted in TE buffer in 100 µM stock solutions.
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B In vivo Chronoamperometry
B.1 Histology
Table B.1 – Table detailing calculations for scaling 120 g fresh rat brain to the Rat Brain
Atlas (Paxinos and Watson, 2005) at various AP loactions
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Table B.2 – Table detailing exact distances of DV points at 7 AP locations in the Rat
Brain Atlas in relation to the 120 g rats
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Table B.3 – The choice of each data point was determined according to histology
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Table B.4 – Continued. The choice of each data point was determined according to histol-
ogy
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B.2 KCl Stimulated DA Release
B.2.1 KCl descriptive statistics
Table B.5 – Descriptive Statistics for KCl stimulation of DA release experiments, no strain
breakdown
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Table B.6 – Descriptive Statistics for KCl stimulation of DA release experiments, with
strain breakdown
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Table B.7 – Continued. Descriptive Statistics for KCl stimulation of DA release experi-
ments, with strain breakdown
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B.2.2 KCl Shapiro-Wilks’ Normality tests
Figure B.1 – Shapiro-Wilks’ normality histogram of amplitudes obtained from KCl stim-
ulation
Figure B.2 – Shapiro-Wilks’ normality histogram of T80 from KCl stimulation
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Figure B.3 – Shapiro-Wilks’ normality histogram of T50 from KCl stimulation
Figure B.4 – Shapiro-Wilks’ normality histogram of Tc from KCl stimulation
Figure B.5 – Shapiro-Wilks’ normality histogram of T100 from KCl stimulation
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B.2.3 Calibration slopes
Table B.8 – Descriptive statistics of calibration slopes
Table B.9 – 1-way ANOVA strain comparison of calibration slopes in the KCl experiments
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B.2.4 Analysis of rat mass
Table B.10 – Strain comparison of rat mass with REC 13
Table B.11 – Strain comparison of rat mass without REC 13
Figure B.6 – Scatterplot of T80 vs amplitudes with the exclusion of Rec 13, r=-0.2055
Figure B.7 – Scatterplot of T80 vs rat mass with the exclusion of Rec 13, r=0.0282
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B.2.5 Analysis of KCl ejection volumes
Table B.12 – Strain comparison of KCl ejection volumes with REC 13
Table B.13 – Strain comparison of KCl ejection volumes without REC 13
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B.2.6 Strain difference in Amplitude
The data quality verification suggested it prudent to perform strain comparisons of ampli-
tudes both with and without the inclusion of the outlier Rec 13 to ensure that the results
obtained were similar. Analysis including Rec 13 was presented in the results. Analysis
excluding Rec 13 is included below.
Analysis of strain difference in amplitudes with the exclusion of Rec 13 showed the
SHR released significantly more DA than the WKY, with the SDs releasing moderate
amounts that were not significantly different from that of the other two strains (Fig. B.9).
This difference occured in the ST (H(2, N=144)=13.0919 p=0.0014) but not the NAc
(H(2, N=27)=3.304246 p=0.1916). Results excluding Rec 13 were similar to those that
included Rec 13. Although the significant difference between the SD and WKY was lost,
the pattern of the data was identical.
Figure B.8 – Strain difference in amplitudes where the SHR released significantly larger
amounts of DA compared to WKY, ∗p=0.0002; Overall: H(2, N=199)=15.5725 p=0.0004
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Figure B.9 – Strain comparison of amplitude without REC 13 Kruskal-Wallis test; H(2,
N=199)=15.5725 p=0.0004
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Table B.14 – Strain comparison of amplitude without REC 13 Kruskal-Wallis test
Table B.15 – Strain comparison of amplitude without REC 13 in ST only Kruskal-Wallis
test
Table B.16 – Strain comparison of amplitude without REC 13 in NAc only Kruskal-Wallis
test
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B.2.7 Strain difference in T80 and Trise
Table B.17 – Strain comparison of T80 as from KCl stimulations
Table B.18 – Strain comparison of Trise as from KCl stimulations
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B.2.8 Strain comparison of parameters when results were aver-
aged per rat
B.2.8.1 Averaged results in the ST
Table B.19 – Strain comparison of averaged amplitudes in the ST with Kruskal-Wallis
Table B.20 – Strain comparison of averaged T80 in the ST with Kruskal-Wallis
Table B.21 – Strain comparison of averaged baselines in the ST with Kruskal-Wallis
Table B.22 – Strain comparison of averaged ejection KCl volumes in the ST with Kruskal-
Wallis
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B.2.8.2 Averaged results in the NAc
Table B.23 – Strain comparison of averaged amplitudes in the NAc with Kruskal-Wallis
Table B.24 – Strain comparison of averaged T80 in the NAc with Kruskal-Wallis
Table B.25 – Strain comparison of averaged baselines in the NAc with Kruskal-Wallis
Table B.26 – Strain comparison of averaged KCl ejection volumes in the NAc with Kruskal-
Wallis
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B.2.9 Analysis of calibrations
Table B.27 – Calibration parameters prior to Rec 39
Table B.28 – Calibration parameters after Rec 39 recording
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Table B.29 – Calibration parameters prior to Rec 40
Table B.30 – Calibration parameters after Rec 40 recording
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B.3 Time of clearance of DA Uptake
B.3.1 DA descriptive statistics
Table B.31 – Descriptive Statistics for exogenously applied DA experiments, no strain
break down
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Table B.32 – Descriptive Statistics for exogenously applied DA experiments, with strain
break down
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Table B.33 – Continued. Descriptive Statistics for exogenously applied DA experiments,
with strain break down
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Table B.34 – Descriptive Statistics for exogenously applied DA experiments, with strain
break down, ‘Large’ amp only
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Table B.35 – Continued. Descriptive Statistics for exogenously applied DA experiments,
with strain break down, ‘Large’ amp only
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B.3.2 Application of exogenous DA Shapiro-Wilks’ Normality
tests
B.4 Analysis of amplitudes
Figure B.10 – Shapiro-Wilks’ Normality tests of controlled amplitudes from application of
exogenous DA
Figure B.11 – Shapiro-Wilks’ Normality tests of T80 from application of exogenous DA
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Figure B.12 – Shapiro-Wilks’ Normality tests of T50 from application of exogenous DA
Figure B.13 – Shapiro-Wilks’ Normality tests of Tc from application of exogenous DA
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Figure B.14 – Shapiro-Wilks’ Normality tests of Trise from application of exogenous DA
Figure B.15 – Shapiro-Wilks’ Normality tests of T100 from application of exogenous DA
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Figure B.16 – Shapiro-Wilks’ Normality tests of baseline from application of exogenous
DA
Figure B.17 – Shapiro-Wilks’ Normality tests of K−1 from application of exogenous DA
Figure B.18 – Shapiro-Wilks’
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B.4.1 Analysis of working electrode calibration slopes
Table B.36 – Descriptive statistics of calibrations slopes of electrodes used in the applica-
tion of exogenous DA experiments
Table B.37 – Strain comparison of calibrations slopes of electrodes used in the application
of exogenous DA experiments
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B.4.2 Strain comparison of of rat mass and amplitudes
Table B.38 – Strain comparison of rat mass in the application of exogenous DA experiments
Table B.39 – Strain comparison of amplitudes in the application of exogenous DA experi-
ments
Table B.40 – Kruskal-Wallis
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B.4.3 Strain comparison of T80 in small and medium amplitude
ranges
Table B.41 – Strain comparison of T80 in the small amplitude range
Table B.42 – Strain comparison of T80 in the medium amplitude range
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B.4.4 Strain comparison of T50 across all amplitude ranges
Table B.43 – Strain comparison of T50 in across all amplitude ranges
Table B.44 – Strain comparison of T50 in the small amplitude range
Table B.45 – Strain comparison of T50 in the medium amplitude range
Table B.46 – Strain comparison of T50 in the large amplitude range
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B.4.5 Strain comparison of Tc
Table B.47 – Strain comparison of Tc across all amplitude ranges
Table B.48 – Strain comparison of Tc in the small amplitude range
Table B.49 – Strain comparison of Tc in the medium amplitude range
Table B.50 – Strain comparison of Tc in the large amplitude range
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B.4.6 Strain comparison of Trise
Table B.51 – Strain comparison of Trise across all amplitude ranges
Figure B.19 – Overall strain difference in Trise of peaks from exogenously applied DA;
H(2, N=306)=9.853931 p=0.0072
Table B.52 – Strain comparison of Trise in the ST only
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Table B.53 – Strain comparison of Trise in the NAc only
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Figure B.20 – Strain comparison of Trise in the NAc; H(2, N=34) =0.8531081 p=0.6628
Table B.54 – Strain comparison of Trise in small amplitude range
Table B.55 – Strain comparison of Trise in medium amplitude range
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Table B.56 – Strain comparison of Trise in large amplitude range
Table B.57 – Strain comparison of Trise in large amplitude range in the ST only
B.4.7 Strain comparison for T100
Table B.58 – Strain comparison of T100 across all amplitude ranges
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B.4.8 Strain comparison of DA volume required to reach am-
plitude range
Table B.59 – Strain comparison of DA volume required to reach small amplitude range
Table B.60 – Strain comparison of DA volume required to reach medium amplitude range
Table B.61 – Strain comparison of DA volume required to reach large amplitude range
Table B.62 – Strain comparison of DA volume required to reach required amplitude range
in ST only
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Table B.63 – Strain comparison of DA volume required to reach required amplitude range
in NAc only
B.4.9 Strain comparison of Baseline levels
Table B.64 – Strain comparison of baseline levels in the exogenously applied DA experi-
ments
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B.4.10 Strain comparison of parameters when results were av-
eraged per rat
B.4.10.1 Averaged results in the ST
Table B.65 – Strain comparison of averaged T80 in the ST in the exogenously applied DA
experiments
Table B.66 – Strain comparison of averaged T50 in the ST in the exogenously applied DA
experiments
Table B.67 – Strain comparison of averaged Tc in the ST in the exogenously applied DA
experiments
Table B.68 – Strain comparison of averaged baseline in the exogenously applied DA ex-
periments
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Table B.69 – Strain comparison of averaged Trise in the ST in the exogenously applied DA
experiments
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B.4.10.2 Averaged results in the NAc
Table B.70 – Strain comparison of averaged T80 in the NAc in the exogenously applied DA
experiments
Table B.71 – Strain comparison of averaged T50 in the NAc in the exogenously applied DA
experiments
Table B.72 – Strain comparison of averaged Tc in the NAc in the exogenously applied DA
experiments
Table B.73 – Strain comparison of averaged baselines in the exogenously applied DA
experiments
Table B.74 – Strain comparison of averaged Trise in the NAc in the exogenously applied
DA experiments
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C Behavioural Response to Methylphenidate
C.1 Running Wheels
C.1.1 Normality histogram of averaged running wheel revolu-
tions
C.1.2 Strain comparison of MPH effect during each dosage pe-
riod
Table C.1 – Strain comparison of MPH effect in dosage period 1, dark cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
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Table C.2 – Strain comparison of MPH effect in dosage period 1, light cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.3 – Strain comparison of MPH effect in dosage period 2, dark cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.4 – Strain comparison of MPH effect in dosage period 2, lightcycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.5 – Strain comparison of MPH effect in dosage period 3, dark cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.6 – Strain comparison of MPH effect in dosage period 3, light cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
194
Running Wheels Chapter C. Behavioural Response to Methylphenidate
Table C.7 – Strain comparison of MPH effect in dosage period 4, dark cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.8 – Strain comparison of MPH effect in dosage period 4, light cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.9 – Strain comparison of MPH effect in dosage period 5, dark cycle; Kruskal-Wallis
and Dunn’s Multiple comparisons tests
Table C.10 – Strain comparison of MPH effect in dosage period 5, light cycle; Kruskal-
Wallis and Dunn’s Multiple comparisons tests
Table C.11 – Strain comparison of MPH effect in dosage period 6, dark cycle; Kruskal-
Wallis and Dunn’s Multiple comparisons tests
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Table C.12 – Strain comparison of MPH effect in dosage period 6, light cycle; Kruskal-
Wallis and Dunn’s Multiple comparisons tests
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D Behavioural Response to Guanfacine
D.1 Running Wheels
D.1.1 Normality histogram of averaged running wheel revolu-
tions
Figure D.1 – Shapiro-Wilks’ Normality test of averaged running wheel revolutions
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D.1.2 Kruskal-Wallis and Dunn’s Multiple comparison test statis-
tics
Table D.1 – Running wheel revolutions in the dark cycle for control groups
Table D.2 – Running wheel revolutions in the light cycle for control groups
Table D.3 – Running wheel revolutions in the dark cycle for treated groups
Table D.4 – Running wheel revolutions in the light cycle for treated groups
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D.1.3 Mann-Whitney U test statistics
Table D.5 – SHR running wheel revolutions in the dark cycle
Table D.6 – SHR running wheel revolutions in the light cycle
Table D.7 – WKY running wheel revolutions in the dark cycle
Table D.8 – WKY dark cycle
Table D.9 – WKY running wheel revolutions in the light cycle
Table D.10 – SD running wheel revolutions in the dark cycle
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D.2.2 Effect of guanfacine treatment on open field parameters
Table D.14 – Mann-Whiteny U tests of guanfacine effect
Table D.15 – Mann-Whiteny U tests of guanfacine effect in SHR
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Table D.16 – Mann-Whiteny U tests of guanfacine effect in WKY
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D.2.3 Strain comparison of open field test activities
Table D.17 – Strain comparison of open field test activities before running wheel placement
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Table D.18 – Strain comparison of open field test activities after running wheel placement
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D.2.3.1 Effects of running wheel placement in SHR
Table D.19 – SHRC Total Distance covered in open field
Table D.20 – SHRG Total Distance covered in open field
D.2.3.1.1 Total distance covered in the open field
Table D.21 – SHRC Total duration in Inner Zone
Table D.22 – SHRG Total duration in Inner Zone
D.2.3.1.2 Total duration spent in Inner Zone
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Table D.23 – SHRC Total frequency into Inner Zone
Table D.24 – SHRG Total frequency into Inner Zone
D.2.3.1.3 Total frequency of entry into Inner Zone
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